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ABSTRACT

The Efficacy of Treatments for Childhood Depression :
An Integrative Review

by

Kurt David Michael , Doctor of Philosophy
Utah State University , 1999

Major Professor : Dr. Susan L. Crowley
Department: Psychology

Prevalence estimates of child depression are substantial and morbidity leads to an
increased risk of recurrence during adolescence and adulthood . Further , early-onset
depression is associated with a number of negative outcomes including: poor physical
health , social and interpersonal impairments , academic problems , substance abuse , future
maladjustment , and suicidal behavior. In light of the prevalence , persistence, and
negative outcomes associated with depression in children and adolescents , several
treatments ranging from psychosocial to pharmacological interventions have been
developed and evaluated. However, the overall efficacy of treatments remains equivocal
because the majority of existing reviews of the child and adolescent depression treatment
literature are narrative in nature, methodologically flawed , and/or present vague or
conflicting conclusions. Although there are a number of good meta-analytic reviews that
indicate that psychotherapy is effective with children and adolescents overall,
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comprehensive meta-analytic reviews focusing on the efficacy of psychological
treatments specifically for depressed youth are nonexistent in the published literature.
A comprehensive sample of studies on the psychosocial and pharmacological
treatment of early-onset depression was located through an extensive literature search.
Articles that met the inclusionary criteria were subsequently analyzed. The outcome data
from 3 7 outcome studies were extracted and converted into effect sizes. Comparisons of
main effects, potential interactions, and other specified variables were conducted. The
overall findings of this meta-analysis indicate that several different psychosocial
interventions for early-onset depression produce moderate to large treatment gains that
are clinically meaningful for many afflicted youth. Further, it appears that psychosocial
treatments are, in general, superior to pharmacological regimens in treating depressed
children and adolescents. However, there is also recent evidence that selective serotonin
reuptake inhibitors such as fluoxetine are efficacious, and they will likely play an
increased role in the management of affective illness in youngsters. The clinical
implications and limitations of these data are discussed and suggestions for future
research are provided.
(164 pages)

v
DEDICATION

I dedicate this dissertation to my wife, Amy, and my son, Kauner. I offer my most
sincere acknowledgment to my wife as she endured a great deal during the course of this
project including my multiple responsibilities, my bizarre nocturnal behaviors, and my
mood swings. Most importantly, my wife assumed the majority role in the care of our
most precious blessing, our son. For this, and for all of the other wonderful things that
she does, I will be forever grateful.

VI

ACKNOWLEDGMENTS

I offer my most sincere appreciation to Dr. Susan Crowley for her support and
guidance throughout this dissertation project. From the project's genesis through the final
defense , Dr. Crowley provided me with encouragement , insight, and analytical advice to
make this the best possible document. In addition, I thank Dr. David Stein, Dr. Pat
Truhn , Dr. Tamara Ferguson, and Dr. Dennis Odell for serving on my committee and for
their thoughtful feedback and assistance throughout the course of the study. Moreover , I
thank Jim Sharpnack , a close friend and colleague, who double-coded each of my studies,
which was essential for computing intercoder reliability estimates. I am also grateful for
Dr. Karl White' s technical suggestions regarding coding, calculation , and interpretive
guidelines for meta-analytic designs . Finally , I extend my sincere gratitude to Karen
Ranson for her assistance in the preparation of this manuscript.
Kurt David Michael

Vll

CONTENTS

Page
ABSTRACT
DEDICATION

.......................................................

n1

.....................................................

v

ACKNOWLEDGMENTS

............................................

v1

LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

lX

LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Xl

CHAPTER
I.
II.

III.

IV.

V.

INTRODUCTION AND PROBLEM STATEMENT

1

REVIEW OF THE LITERATURE . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4

Depression in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treatment of Childhood Depression . . . . . . . . . . . . . . . . . . . . . . . .
Treatment Variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purpose and Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4
19
43
56
57

METHODOLOGY

........................................

59

Population and Sample . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Instrumentation and Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

59
60
64
70

RES UL TS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

71

Descriptive Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intercoder Agreement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Main Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis of Study Variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

71
75
75
81

DISCUSSION

............................................

98

Vlll

Page
Main Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Study Variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Summary and Clinical Implications . . . . . . . . . . . . . . . . . . . . . . . .
Limitations and Future Research . . . . . . . . . . . . . . . . . . . . . . . . . .

98
106
118
120

....................................................

122

APPENDIX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

144

VITA

147

REFERENCES

.... . . ... .. ..... ..... ... .. .......................

... .. .. ...

IX

LIST OF TABLES

Table

Page

1.

Frequency and Percentage of Study Characteristics . . . . . . . . . . . . . . .

73

2.

Intercoder Agreemant and Cohen's Kappa of Study Variables

......

76

3.

Overall Mean Effect Sizes at Posttreatment

.....................

77

4.

Overall Mean Effect Sizes at Follow-Up

.......................

77

5.

Effect sizes at Posttreatment and Follow-Up for Controlled
Psychosocial Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

78

Effect Sizes at Posttreatment and Follow-Up for Each
Pre- and Postpsychosocial Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

79

Effect Sizes Comparing Active Versus Placebo Positive
Rates for Controlled Pharmacological Studies . . . . . . . . . . . . . . . . . .

82

8.

Mean Effect Sizes Based on Average Age of Sample

84

9.

Interaction Between Effect Sizes and Sex in
Psychosocial Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

86

Interaction Between Effect Sizes and Referral Source in
Psychosoci~Studies
... .. .... ... .... ..... . .... .. .. .. . ... ...

87

11.

Mean Effect Sizes Based on Treatment Setting

..................

88

12.

Mean Effect Sizes by Treatment Modaltiy in Controlled
Psychosocial Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

88

13.

Mean Effect Sizes by Treatment Modality in Pre- and Poststudies

89

14.

Mean Effect Sizes by Medication in Pharmacological Studies

90

15.

Within-Study Effect Sizes Comparison of
Assessment Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

92

6.

7.

10.

...

x

Page
16.

17.

Mean Effect Sizes by Level of Training in
Psychosocial Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

94

Mean Effect Sizes by Level of Severity in
Psychosocial Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

96

XI

LIST OF FIGURES

Figure
1.

2.

Page
DSM-IV (APA , 1994) symptom overlap: major depressive episode
and generalized anxiety disorder
...............................

16

Relationship between study quality and standard mean difference
effect sizes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

97

CHAPTER I
INTRODUCTION AND PROBLEM STATEMENT

Although childhood depression was not a recognized phenomenon until recently,
it is now considered to be an important area of research in child psychopathology. Prior
to its recognition, various researchers and clinicians questioned whether depression as a
disorder could develop in children (Rie, 1966), or as described depressive equivalents
(e.g., "masked depression") that were purportedly manifested by overt behavioral
problems such as delinquency, hyperactivity, and aggression (Cytryn & McKnew, 1972;
Glaser, 1967). However, based on current research, depressive disorders in children are
indeed real phenomena (Kovacs, 1997). Depression in children, for the most part, is
characterized and identified in many of the same ways as depression in adults (American
Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders [4th ed.],
1994; Kovacs , 1996), and it adversely affects the lives of many youth.
Estimates of the prevalence of child and adolescent depression in the general
population are substantial , ranging from 0.4% to 8.3% (Anderson, Williams, McGee , &
Silva, 1987; Birmaher et al., 1996b; Fleming & Offord, 1990; Kashani et al., 1983;
Lewinsohn, Clarke, Seeley, & Rohde, 1994). Among groups of clinically referred
children, the prevalence rates are even higher (Poznanski & Mokros , 1994). Early-onset
depression is often persistent and leads to an increased risk of recurrence during
adolescence and adulthood (Kovacs, Obrosky, Gatsonis, & Richards, 1997). Further,
depression in children and adolescents is associated with negative outcomes including:
poor physical health, social and interpersonal impairments, academic problems, substance
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abuse, future maladjustment, and suicidal behavior.
In light of the prevalence, persistence, and negative outcomes associated with
depressive disorders in children, several researchers and clinicians have developed and
implemented various treatments for childhood depression ranging from psychosocial
interventions to pharmacological interventions.
Although there are a number of good meta-analytic reviews that indicate that
psychotherapy is generally effective with children and adolescents who present with a
broad array of problems (e.g., Casey & Berman, 1985; Weisz, Weiss, Han, & Granger,
1995), comprehensive reviews investigating the efficacy of psychosocial treatments for
child and adolescent depression are currently nonexistent in the published literature .
In terms of pharmacological interventions for depressed youth, a number of open
and controlled clinical trials have been conducted. In addition, the prescription of
psychotropic medications for depression in children and adolescents has become a widely
accepted practice. However, the efficacy and safety of such practices remain the subject
of much debate and controversy, due to methodological problems, developmental
considerations, and limited empirical support. Furthermore, there is a paucity of data on
the comparison of pharmacological and psychosocial interventions for child and
adolescent depression.
Current reviews of the outcome studies for childhood depression have not been
adequate for guiding research, policy, and practice because many of the reviews are
narrative in nature, methodologically flawed, and/or present vague or conflicting
conclusions. Furthermore, while some of the efforts to review and synthesize the body of
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literature on the treatments for depressed youth have answered some questions, there are
many more questions left unanswered. From clinical and empirical perspectives, it is
important to know whether outcomes covary with study and sample characteristics. For
instance, which types of treatments are the best and for whom? Does the age of the child
matter? Do comorbid conditions impact the outcomes? Does it make a difference
whether the children have been identified as suffering from depressive symptomatology
as opposed to a depressive disorder? Are the findings from a school-based sample
generalizable to a clinic-based sample? What is the overall efficacy of pharmacological
treatments for child and adolescent depression? How do psychosocial interventions
compare with pharmacological treatments? Is there evidence of differential efficacy
when a number of important variables are considered (e.g., age, sex, severity,
methodological factors)?
If a comprehensive, methodologically sound review of the literature on the

efficacy of psychosocial and pharmacological treatments for childhood depression
existed, researchers and clinicians would have a better understanding of which treatments
are effective in ameliorating depressive symptomatology in children as well as how
outcomes covary with study and sample characteristics . Furthermore, a more
comprehensive review would help to guide both intervention efforts and future empirical
studies on the treatment of depressive disorders in children. Therefore, in the present
study, an integrative review of early-onset depression treatments was conducted.
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CHAPTER II
REVIEW OF RELATED LITERATURE

The present literature review was conducted to establish support for the need to
complete a comprehensive, methodologically sound review of the outcome studies on the
psychosocial and pharmacological treatments of childhood depression. A definition and
brief history of childhood depression are presented, followed by a review of the
prevalence , longitudinal course, correlates, and the assessment and diagnosis of childhood
depressive disorders. For purposes of clarity, the term "children" is used inclusively
subsuming children and adolescents between 6 and 18 years of age. However , when agerelated distinctions are made, young children are referred to as those who are between 6
and 12 years old, whereas adolescents are identified as those who are between the ages of
13 and 18. Finally, a review of the current knowledge regarding the psychological and
pharmacological treatment of childhood depression is included .

Depression in Children

As a symptom, depression is characterized by a dysphoric or unhappy mood state.
Defined as a syndrome, depression consists of a constellation of behavioral and emotional
symptoms that do not simultaneously exist by chance (Rehm & Tyndall, 1993). For
example, when depressed mood is combined with labored psychomotor functioning,
cognitive difficulties , and a lack of motivation, these symptoms, if experienced
simultaneously , are often construed as evidence of a depressive syndrome. Establishing
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the existence of a depressive disorder depends largely upon the duration and severity of
the symptoms as well as whether there is a pattern of marked impairment in important
areas of functioning (e.g., academic, social, physical).
From a historical perspective, there have been a limited number of empirical
efforts to investigate depressive illnesses in children because until recently, most
researchers and clinicians debated about the nature and existence of childhood depression
(Kaslow & Rehm, 1991). Although today there is a general consensus among researchers
and clinicians that childhood depression is similar to adult depression, three historical
conceptualizations of depression in children contributed to the lack of previous empirical
efforts in the area. First, based on the classic psychoanalytic viewpoint that was
predominant during the early part of this century, depression could not exist in children
because they lacked the mental structure (i.e., superego) necessary for the development of
depression. Rie ( 1966) pointed out that a number of psychoanalysts believed that
depression resulted from the discrepancy between the real self and the ideal self.
However, based on this conceptualization, a stable self-representation does not develop
until adolescence, and thus the major components of depression cannot develop during
childhood .
The second conceptualization of childhood depression, popular during the 1960s,
included depressive equivalents or "masked depression," which were supposedly
manifested by a variety of behavioral problems such as temper tantrums, hyperactivity,
running away, learning disabilities, enuresis, and school failure (Cytryn & McKnew,
1972; Glaser, 1967). The major criticism of this conceptualization was the fact that
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virtually any behavioral problem could be construed as masked depression , which
seriously hampered a clinician ' s ability to discriminate between depressive and
nondepressive behavioral problems (Carlson & Cantwell, 1980). The third
conceptualization of childhood depression worthy of mention was the notion that
depressive symptoms (e.g., depressed mood) in children were merely transitory and not
indicative of a depressive disorder (Lefkowitz & Burton, 1978). This position was most
popular prior to the publication of American Psychiatric Association, Diagnostic and
Statistical Manual of Mental Disorders (3rd ed.) in 1980, in which formally diagnosing
children with depressive disorders was sanctioned by a number of professional groups
(DSM-III, 1980). However , based on several longitudinal studies of children with
depressive disorders , it is clear that these conditions are often more chronic and persistent
than previously thought (e.g., Fleming , Boyle , & Offord , 1993; Hughes , Preskom , Wrona ,
Hassanein , & Tucker , 1990; McCaule y et al., 1993; McGee & Williams , 1988).
Despite the aforementioned conceptualizations that challenged the legitimacy of
depression in children , Kovacs (1989) suggested that there is now compelling evidence
from several empirical studies that children suffer from depression , regardless of whether
it is defined as a symptom (depressed mood) , a syndrome (constellation of symptoms) , or
a disorder (diagnosis based on the severity and duration of symptoms) as reflected in
current nosological systems such as the DSM-IV , (1994).

Prevalence and Longitudinal Course
Prevalence estimates of child and adolescent depression are varied , ranging from
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0.4% to 8.3% (Birmaher et al., 1996b; Garrison et al., 1997; Lewinsohn et al., 1994;
Silver , 1988). Further, the prevalence estimates for depression in child samples are
reportedly lower than in adolescent cohorts (Harrington , Rutter, & Fombonne , 1996).
However, it remains unclear whether the lower prevalence rates in child samples are due
to actual differences in prevalence or an artifact of how developmental differences (e.g.,
language, self-understanding) might impact the assessment of depressive disorders in
children (Cicchetti & Schneider-Rosen, 1986). In terms of sex differences in early-onset
depressive disorders , it appears that males and females are equally affected during
childhood (Birmaher et al., 1996b). However , as young children move into adolescence,
the prevalence rates begin to shift whereby adolescent females experience depressive
sequelae at twice the rate of their male counterparts , a sex ratio that closely resembles that
of adult samples (Cicchetti & Toth, 1998).
In a critical evaluation of epidemiological studies of childhood depression ,
Fleming and Offord ( 1990) suggested that the variation in prevalence rates is due
primarily to methodological flaws in the research designs including sampling bias, small
samples , inconsistent measurements, age parameters, and diagnostic procedures. In light
of these problems , the authors suggested that it is difficult to draw firm conclusions about
the prevalence of childhood depression (Fleming & Offord, 1990). Nonetheless , even the
lowest estimates are substantial , especially when one considers the long-term risk of
depressive disorders in children and adolescents . For example, Kessler et al. (1994)
reported that the lifetime prevalence of major depressive disorder (MDD) during
adolescence is 15-20%, an estimate similar to adult samples .
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The longitudinal course of childhood depression has received increased attention
in the empirical literature over the last several years. Early studies characterized
depressive disorders as transient, normal developmental reactions to stress and viewed
them as unstable when compared to the relative stability of behavioral disorders (Fischer,
Rolf, Hasazi, & Cummings, 1984; Graham & Rutter, 1973; McGee et al., 1985),
especially conduct disorder (Offord et al., 1992). Clarizio (1984) posed the question of
whether childhood depression is a chronic, transitory, or recurring condition . According
to Clarizio, the answer depends on whether the sample under investigation is based upon
a normal or clinical population, the severity and type of the depression, and how long the
sample is followed.
In addition, determining the longitudinal course of depression depends upon
whether one is measuring depressive symptomatology or attempting to determine whether
a depressive disorder is present. The specific depressive symptomatology can vary over
time and the determination of whether a disorder is present may reflect a diverse array of
symptom clusters that change in frequency and severity above and below a particular
diagnostic threshold. Kazdin (1990) described this phenomenon as the distinction
between dimensional (symptomatology) versus categorical (diagnostic) assessment.
Despite the aforementioned considerations, several recent longitudinal studies have
provided evidence to support the idea that depressive disorders are more persistent than
previously thought (Kovacs, 1989).
In one of the first longitudinal investigations of depressive disorders in children,
Kovacs et al. ( 1984) reported that a significant number of youngsters remained
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symptomatic for 5 years or more , even when treatment was implemented. In addition ,
McGee and Williams ( 1988) reported that 31 % of depressed 9-year-olds were found to
have persistent depressive disorders after 2- and 4-year follow-ups , at the ages of 11 and
13, respectively. In another longitudinal study, Nolen-Hoeksema, Girgus, and Seligman
(1992) found that in a large sample of children who initially met criteria for serious levels
of depression during initial testing, approximately 40% remained at that level for 6
months to 2 years .
Furthermore , DuBois , Feiner, Bartels , and Silverman (1995) investigated the
course and stability of self-reported depressive symptoms in a community sample of 435
school-age children . The authors reported that upon initial assessment , 10% of the
sample presented with clinicall y significant symptoms of depression . Two years later , the
authors reported that 32% of the "clinical " sample continued to endorse clinically
significant levels of depressive symptomatology and evidenced a greater pattern of
impairment across several areas of functioning. A number of other longitudinal
investigations have augmented the notion that depressive disorders in children and
adolescents are often characterized by a persistent , chronic course (e.g., Fleming et al. ,
1993; Kovacs , Akiskal , Gastonis, & Parrone , 1994; Kovacs et al., 1997; Lewinsohn et al.,
1994). Thus , the findings from a number of empirical studies appear to contradict the
belief that young children only suffer from brief and episodic depression, highlighting the
importance of providing effective treatments early during the course of the illness .

IO
Correlates of Depression in Children
Several researchers have asserted that depressive disorders in children typically
result in significant distress , misery , and negative outcomes in young people including:
diminished self-esteem (Kazdin , 1988), poor physical health (Costello et al., 1988),
family dysfunction (Kashani , Burbach , & Rosenburg , 1988), increased risk for substance
abuse (Kovacs , Goldston , & Gatsonis , 1993), future psychological problems (Kovacs,
1985), and a substantial risk for morbidity and mortality across the lifespan (Fleming &
Offord , 1990; Harrington & Vostanis , 1995). There is compelling evidence that children
and adolescents who suffer from depression have a variety of problems in daily living ,
ranging from unsatisfying interpersonal relationships (Puig-Antich et al., 1985) to
noteworthy declines in academic perfom1ance (Fleming , Offord , & Boyle , 1989), and an
increased risk for dropping out of school (Fleming & Offord , 1990).
Furthermore , Puig-Antich et al. (1985) reported that depressed children had more
severe family , peer-related , and social problems when compared to nondepressed
controls . Kovacs (1997) suggested that "the social problems of depressed youngsters may
be related to or derive from their interpersonal behavior and impact on others " (p. 288).
That is, impaired social functioning, which is often associated with depression , may both
contribute to and be caused by depressive sequelae. For example , in an observational
study of children in a school setting , Altmann and Gotlib (1988) reported that while
depressed children attempted to engage in social exchanges , they spent considerable
amounts of time alone, thus limiting the amount of potentially reinforcing social contact
and the opportunities to practice and develop age-appropriate social skills (Kovacs &
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Goldston, 1991). Similarly, Goodyer, Germany, Gowrusankur, and Altham (1991)
reported that early-onset major depressive disorder interferes with the acquisition of
problem-solving skills in children and adolescents.
In studies where the relationship between depression and impaired family
functioning has been examined, greater amounts of conflict (i.e., marital , sibling, parentchild) have been reported in families with depressed versus nondepressed youngsters
(e.g ., Beck & Rosenberg , 1986; Kaslow, Rehm, Pollack, & Siegel , 1988). In addition ,
Kovacs (1997) suggested that the developmental, interpersonal, and social deficits
associated with childhood depressive illnesses can have "ominous consequences in the
context of family life by disrupting the attachment bond between parent and child"
(p. 289).
Another reason to be concerned about child and adolescent depression is the
association between clinical mood disturbances and suicide (Bettes & Walker , 1986; Rao,
Weissman , Martin , & Hammond , 1993). Kovacs et al. (1993) reported that depressive
disorders were associated with significantly higher rates of suicide than were
nondepressive disorders in a mixed sample of children between the ages of 8 and 13. In
addition, Kovacs et al. ( 1993) found that "in the presence of affective disorders , comorbid
conduct and/or substance abuse disorders further increased the risk of suicide attempts"
(p. 8).
In sum , depressive sequelae in children and adolescents are correlated with a
plethora of impairments in developmental, intrapersonal, social , academic, and familial
domains. These impairments, combined with the chronicity and likelihood of recurrence
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of early-onset depression, provide ample justification for the need to develop, implement,
and evaluate various interventions for depressed youth.

Assessment and Diagnosis
The efficacious treatment of virtually every psychological disorder is contingent
upon an accurate assessment of the pathognomonic symptoms of that disorder
(Achenbach, 1985) . In addition, the process of assessment can have a profound impact
on treatment outcome studies because the assessment and diagnostic procedures are used
to (a) guide the inclusion/exclusion of subjects and (b) provide the basis for pretreatment,
posttreatment, and follow-up evaluations of treatment effects (i.e., dependent measures).
Thus, it is crucial to attend to these assessment issues when attempting to accurately
assess , diagnose, and ultimately treat child psychological sequelae . In the case of
childhood depression, the historical lack of consensus regarding its nature and existence
has hindered the establishment of consistent diagnostic criteria and has impeded the
development of treatment regimens. However, when the American Psychiatric
Association (1980, 1987) revised the DSM-III, DSM-IIIR during the 1980s, the diagnosis
of depressive disorders in children was formally sanctioned.
In the most recent version of the DSM-IV (APA, 1994), a diagnosis of either a
depressive episode or a depressive disorder depends upon whether a minimum number of
criteria (i.e., 5 out of 9) have been met. The criteria are made up of several emotional,
cognitive, and behavioral symptoms, such as depressed mood, difficulty concentrating,
changes in appetite, sleep disturbance, fatigue, thoughts of death, and impaired academic,
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interpersonal, and social functioning. While the authors of the DSM-IV (APA, 1994)
suggested that
the core symptoms of a Major Depressive Episode are the same for
children and adolescents [as they are for adults] ...certain symptoms such as
somatic complaints, irritability, and social withdrawal are particularly
common in children. (p. 324)
Furthermore, Carlson and Garber (1986) suggested that developmental factors (e.g.,
language, cognitive abilities, emotional insight) must be taken into account when
attempting to identify and classify childhood depression. Nonetheless, Kovacs (1996)
reported that there is evidence that depressive disorders "in childhood and in the later
years of the life span capture the same psychopathological entity" (p. 711).
Despite more consistent and professionally sanctioned diagnostic criteria, the
accurate assessment and diagnosis of depressive disorders in children is complicated by
several factors. First, there are a number of different methods for assessing depressive
symptomatology in children including direct behavioral observation, behavior rating
scales, sociometric approaches, clinical interviews, and self-report measures. Each of
these methods has limitations. For example, Merrell (1994) reported that the evaluation
of childhood depression has typically relied upon the verbal or written reports of parents,
teachers, and other significant figures in the child's environment "due to the supposedly
questionable accuracy of information obtained through self-report methods" (p. 194).
However, because depressive disorders are, in great measure, subjective perceptions of
internal distress, they are often not readily or reliably identified by external observers (La
Greca, 1990) and there is often disagreement among informants (Achenbach,
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McConaughy, & Howell, 1987; Sanford, Offord, Boyle, Peace, & Racine, 1992). At the
same time, the potential limitations of self-report measures include biased response styles
(e.g., social desirability; Borg & Gall, 1989), children's inability to understand and report
their emotions (Clarizio, 1984), and whether the instrument has an age-appropriate
reading level (Prout & Chizik, 1988). In light of these issues, La Greca (1990)
emphasized the importance of a multimethod-multisource assessment that takes into
account, "the limitations inherent in any one procedure" (p. 8). However, from a
historical perspective, assessment protocols utilizing multiple methods and multiple
sources across settings have been the exception rather than the rule (Merrell, 1994).
A second factor that complicates the assessment and diagnosis of depression in
children is the fact that depressive disorders are a heterogeneous combination of symptom
clusters that vary in presentation, duration, and severity from child to child (Cicchetti &
Toth, 1998). Essentially, two different children can have the same diagnosis, but present
with different manifestations of the disorder. For example, in order to meet the DSM-IV
(AP A, 1994) criteria for a diagnosis of major depressive episode, an individual must
present with a minimum of five out of nine criteria (i.e., symptoms) . It is conceivable
that two children could be diagnosed with only a single common symptom. Therefore,
both children can be diagnosed appropriately with major depressive episode; however,
their manifestations of major depressive episode are quite different. Subsuming children
with different symptom presentations into a broader diagnostic category leads to an
inevitable loss of data regarding the true variability and unique symptom constellations
presented across children suffering from depressive sequelae. Subsequently, treatment

15
decisions might be based on broad assumptions about major depressive episode without
considering the specific needs of individual children.
A third factor that complicates the assessment and diagnosis of depression in
children is the issue of comorbidity. According to Stedman's Medical Dictionary (1995)
comorbidity is defined as "a concomitant but unrelated pathological or disease process"
(p. 174). For example, an individual might be suffering from both lung cancer and
Hepatitis Bat the same time and thus be considered to have comorbid medical illnesses.
These two disease processes are essentially independent of one another, with different
etiologies, symptom presentations, and progression patterns.
While the medical definition of comorbidity implies that illnesses are concomitant
but unrelated, the use of the term comorbidity in the psychological and psychiatric
literature is less well-defined. Unlike many medical illnesses, psychological disturbances
are not discrete illnesses and are therefore more difficult to assess, diagnose, and classify,
due, in part, to the overlapping nature of the various symptom clusters (Adams &
Cassidy, 1993). For example, two disorders in the DSM-IV (APA, 1994), major
depressive episode and generalized anxiety disorder, have overlapping diagnostic criteria
including: irritability, difficulty concentrating, sleep disturbance, and fatigue (see Figure
1). Consequently, children who present with these symptoms would meet some of the
diagnostic criteria for MDE while simultaneously satisfying some of the diagnostic
parameters of generalized anxiety disorder (GAD), thus making an accurate
differentiation between the two diagnoses problematic. Angold and Costello ( 1993)
stated that researchers and clinicians must evaluate whether patterns of comorbidity are
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Figure 1. DSM-IV (APA , 1994) symptom overlap : major depressive episode and
generalized anxiety disorder.

"artifacts of the methods of data collection , data aggregation for diagnostic purposes , or
the nosology itself ' (p. 1786). In sum, various authors have suggested that assessment
methods should be broad enough (e.g., multiple instruments) to accuratel y identify
several different constellations of symptoms , especially when there is evidence of
comorbidity (Achenbach, 1985; Costello , 1986; Reynolds , 1992a, 1992b).
In spite of these diagnostic limitations , there is mounting evidence that the
existence of more than one psychological disorder in the same child is prevalent and can
lead to poorer outcomes . For example, Offord et al. ( 1992) followed a community
sample of over 1,000 children between 4 and 12 years old and reported that children with
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multiple disorders tend to "have a worse outcome years later compared with the singledisorder group" (p. 921 ). In a more recent longitudinal study involving over 1,000
children who were followed from birth to age 21, Newman et al. (1996) reported that
nearly half of the subjects who evidenced a psychiatric disorder during the course of the
study also had comorbid diagnoses at the age of 21. Further, the authors reported that
"comorbidity was associated with severity of impairment" (p. 552).
Current comorbidity estimates for depression and anxiety in children range from
15.9% to 61.9% (Brady & Kendall, 1992). Anderson et al. (1987) examined a
nonclinical sample of 63 children and found that 15.9% qualified for both an anxiety
disorder and a depressive disorder. However , Costello et al. ( 1988) reported much lower
estimates of comorbidity in a nonclinical group of pediatric primary care patients , with
coexisting symptoms of depression and anxiety appearing in 0.8% of the sample. In
clinical samples, the comorbidity rates have been much higher. In a sample of
hospitalized children , Carey, Finch , and Imm (1989) reported that 55.2% of the sample
had diagnosable disorders of both depression and anxiety. Furthermore, Strauss, Last ,
Hersen, and Kazdin (1988) reported that in a group of outpatient children and adolescents
who presented with anxiety disorders , 28.3% of the sample also met criteria for
depressive disorders.
Based on the aforementioned findings , there is a great deal of variation in the
comorbidity estimates of depression and anxiety in children and adolescents. The
variation has been attributed to "rather crude diagnostic criteria" (Angold & Costello,
1993, p. 1786), unreliable data collection techniques (Garfield, 1993), similarity in self-
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report rather than construct overlap (Norvell , Brophy, & Finch, 1985), and the fact that
depression and anxiety might be clinically related (Clark, Beck, & Stewart, 1990;
Ollendick & King, 1994). Despite the discrepant findings, several authors have suggested
that the overall comorbidity rates are large enough to be considered clinically meaningful
(Kendall, Kortlander, Chansky, & Brady, 1992; Newman et al., 1996; Reynolds, 1992b).
In sum, the assessment and diagnosis of depression in children is a complex
process with a number of limitations. Nonetheless, it is incumbent upon researchers and
clinicians to understand this process and to use the best methods available in order to best
serve these children. In light of the variation in comorbidity estimates and the diverse
presentation of symptom constellations, various researchers have recommended
assessment practices that emphasize broad-band instruments and the solicitation of
information from several sources (Achenbach et al., 1987; Finch & Rogers , 1984;
Kazdin , 1988; Reynolds, 1992c). Similarly, interventions may be differentially effective
for various children (i.e., comorbid vs. no comorbid diagnoses); thus clinicians and
researchers must remain mindful of these considerations when evaluating the efficacy of
treatments.

Summary
Although childhood depressive disorders were not recognized until recently, it is
now known that depression in children is a serious problem that has critical ramifications
for a large number of young people. Depressive disorders typically result in a great deal
of distress and suffering in children, which, for some, can lead ultimately to fatal
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consequences in the case of suicide. In light of the prevalence , persistence , and serious
consequences associated with childhood depression , mental health professionals have an
obligation to provide expeditious and effective treatments to young people suffering from
depressive disorders .

Treatment of Childhood Depression

Several treatments have been developed for depression in children ranging from
group-based cognitive-behavioral interventions to pharmacotherapies . While there are a
growing number of well-controlled clinical trials, most of the early attempts to document
the efficacy of treatments for child and adolescent depression were based upon clinical
experience , case reports , and extrapolations from the adult literature (Mueller &
Orvaschel , 1997; Speier, Sherak , Hirsch , & Cantwell , 1995). In contrast , much more is
known about the treatment of adult depressive disorders since a large number of wellcontrolled clinical trials have been conducted , which in turn , have been integrated and
summarized via meta-analytic studies (e.g., Robinson , Berman , & Neimeyer , 1990). In
light of the paucity of clinical trials for child and adolescent depression relati ve to adult
samples and the lack of any published , methodologically sound integrative reviews , the
current state of knowledge regarding the efficacious treatment of childhood depression is
unclear . This section includes a review of the adult and child literatures regarding the
treatment of depression .

Adult Literature
A number of treatments for depression have been empirically studied and
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validated for adult populations. For instance, the National Institute of Mental Health
(NIMH) sponsored a large, multisite, controlled clinical trial that compared the efficacy
of four treatments for adult depression, including imipramine plus case management
(IMI-CM), a placebo plus case management (PLA-CM), and two types of psychotherapy
(Treatment of Depression Collaborative Research Program; Elkin, 1994). The two types
of psychotherapy implemented were cognitive-behavioral therapy (CBT) and
interpersonal therapy (IPT). While there is some variation in the components of CBT, the
ultimate goal of this therapeutic approach is to identify irrational and dysfunctional
thoughts, become aware of how they lead to depressive feelings and behavior, and to
modify thinking patterns (Beck, Rush, Shaw, & Emery, 1979). IPT, on the other hand,
focuses on dysfunctional patterns of relating to others in a variety of social milieus with
the main goal of identifying and modifying problematic interpersonal tendencies (Elkin,
Parloff, Hadley, & Autry, 1985). In general, the findings indicated that either type of
psychotherapy was as effective as medication and more effective than PLA-CM in
reducing depressive symptomatology in a group of250 outpatient adults. Elkin (1994)
reported that "there were ...no statistically significant differences between the two
psychotherapies or between either of them and IMI-CM" (p. 119).
Furthermore, there have been a number of large integrative reviews investigating
the efficacy of various treatments for adult depressive disorders. For example, Robinson
et al. (1990) conducted a comprehensive review of 58 controlled outcome studies of
various psychotherapeutic treatments for adult depression (e.g., cognitive-behavioral,
psychodynamic, client-centered, pharmacologic). Based on their sample of studies, the
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authors reported a standard mean difference effect size (ES; mean of the treatment group
minus the mean of the control group divided by the control group or pooled standard
deviation) of 0.74 when comparing psychotherapy clients and no treatment controls at
posttreatment. This finding indicates that the average treated client was better off at
posttreatment than approximately 77% of the untreated clients . Robinson et al. concluded
that depressed adults derive substantial and long-lasting benefits from psychotherapy.
They added that the benefits of psychotherapy were at least as effective as medication and
that no specific type of psychotherapy was superior to another in assuaging depression in
adult samples. Thus, important questions remain regarding what treatments are best for
whom even with adults.
Despite the fact that there are empirically supported methods of treating adult
forms of depression , the generalization of these findings to children might be problematic
in light of the developmental, cognitive, emotional, and age differences observed between
adults and children (Speier et al., 1995). Yet, to a large extent, the adult literature has
been used to guide the efforts to treat child and adolescent depression (Holmes &
Wagner, 1992; Mueller & Orvaschel, 1997). While this extrapolation approach makes
intuitive sense, making inferences from the adult literature to the child literature requires
a leap of faith, a leap that has not been empirically validated to date.

Child Literature
While the psychotherapy literature for children and adolescents is not nearly as
substantial as the adult literature, there have been a large number of treatment studies for
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youth who present with a broad array of problems. Further, the results from several
studies have been synthesized in large meta-analytic reviews of the overall efficacy of
psychotherapy with children and adolescents. For example, Casey and Berman (1985)
reviewed 75 studies published between 1952 and 1983 and reported a standard mean
difference ES of O.71, indicating that the average treated child scored better after
treatment than approximately 76% of control-group children. However, there were no
studies that specifically addressed depression in children. In another large meta-analytic
review, Weisz, Weiss, Alicke, and Klotz (1987) examined the outcomes of 108 welldesigned treatment studies published between 1952 and 1983 involving children between
the ages of 4 and 18 years of age. The authors reported a standard mean difference ES of
0.79, indicating that the average child who received treatment was at the 79th percentile
of control-group children. Kazdin, Bass, Ayers, and Rogers (1990) surveyed the
published literature between 1970 and 1988 and included a broad sample of 223 studies
in their analysis. When comparing treated versus untreated controls (64 studies), Kazdin
et al. reported a standard mean difference ES of 0.88, indicating that the average child in
the treatment group was better off at posttreatment than 81% of the control-group
children. However, the investigators in all of the aforementioned reviews did not
specifically address the issue of treating child and adolescent depressive disorders or they
collapsed "depression" studies into more broadly defined categories (e.g., internalizing,
emotional problems), making the extraction of specific data regarding the efficacy of
depression treatment problematic. For example, Kazdin et al. (1990) categorized 16% of
the original sample of 223 studies as treatment trials for "internalizing" problems (e.g.,
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anxiety, withdrawal, emotional disturbances, depression) .
Only one large published integrative review was located that addressed the issue
of treating child and adolescent depression. In a meta-analytic review of 150 outcome
studies on child and adolescent psychotherapy, Weisz et al. (1995) included six controlled
outcome studies of child and adolescent depression and reported a standard mean
difference ES of 0.64, indicating that the average child who received treatment for
depression was better off than approximately 74% of children who did not. In a more
recent investigation, Reinecke, Ryan, and DuBois (1998) analyzed many of the same
studies (i.e., four of the six) included by Weisz, Weiss, et al. (1995) and included two
others (i.e., Lerner & Clum, 1990; Wood, Harrington , & Moore, 1996) in a highly
focused meta-analytic review of controlled cognitive-behavioral interventions for
depressed adolescents. Reinecke et al. (1998) reported a standard mean difference ES of
1.02, indicating that the average treated adolescent was better off at posttreatment than
approximately 84% of the control subjects . Although the findings from these
investigations are important, Weisz, Weiss et al. (1995) included only six studies and they
did not specifically address how the outcomes of child depression studies might covary or
interact with other variables (e.g., age, sex, type of treatment). In terms of the metaanalytic review by Reinecke et al. (1998), the sample of studies analyzed were not only
similar to a previously published meta-analysis, but the findings were limited in the sense
that only cognitive-behavioral interventions for adolescents were included. Thus, the
findings were far from complete. Essentially, one is left to ponder several important
questions regarding the efficacy of psychosocial treatments for child and adolescent
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depression. For example, what treatments are the most effective and for whom? Does
the age of the child make a difference? Do other variables such as length of treatment,
therapist variables, and comorbid conditions make a difference? Is there differential
efficacy for those suffering from depressive symptomatology versus a diagnosed
depressive disorder? Furthermore, how do psychosocial interventions compare with
pharmacological treatments? In sum, is there evidence of differential efficacy when a
number of important variables are considered such as age, sex, severity, and
methodological factors?
In one other systematic review worthy of mention, Black-Cecchini ( 1996)
analyzed 13 outcome studies investigating the efficacy of group-based social skills
interventions for depressed youth as part of an unpublished doctoral dissertation. By
using meta-analytic procedures, Black-Cecchini reported that the social skills group
interventions produced moderate to large effects (i.e., average ES 0.76) in terms of
ameliorating depressive symptomatology in depressed children and adolescents primarily
from school samples. Nonetheless, Black-Cecchini (1996) suggested that some of the
outcomes covaried with certain design and sample characteristics. For example, BlackCecchini cross-tabulated the quality of the studies with the outcomes and found that
"inferior" studies had the highest mean effect sizes when compared to the higher quality
studies. In addition, Black-Cecchini noted that it was difficult to determine how other
variables (age, ethnic status, type of treatment) covaried with the outcomes because either
the data were not reported or the data were poorly defined or quantified. Further, BlackCecchini described some of the limitations found in the sample of outcome studies
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including a paucity of investigations which included preadolescent samples (7-12 age
group; N = 4) and an overreliance on self-report measures. In essence, Black-Cecchini's
analysis provided some provocative ideas about the nature and course of the present
study.

Psychosocial Treatments for Childhood
Depression
As mentioned previously, a variety of psychosocial treatment regimens for
depressed children have been described in the literature including: psychoanalytic,
behavioral, familial, group, cognitive, relaxation, social skills training, problem-solving
training, and multimodal therapies. For instance, in one case study, Frame, Matson,
Sonis, Fialkor, and Kazdin ( 1982) used behavior therapy to treat a 10-year-old depressed
child and reported that certain behavioral indices associated with depression (e.g.,
suicidal gestures , labored psychomotor functioning) improved during the course of
treatment and after a 12-week follow-up. Other investigators have reported similar
results when using behavioral regimens to treat depressed youth (e.g., Matson, 1982).
In addition, some of the behavioral modalities are downward extensions of
interventions originally intended for adults. For example, a behavioral method of treating
depression in adults is based on the premise that depression results from low rates of
environmental reinforcement, which is manifested by diminished activity levels (Costello,
1972; Lewinsohn, 1974). Interventions designed to increase activity levels, especially
pleasant activities, purportedly led to an increase in the amount of response-contingent
reinforcement for clients, resulting in a decrease in depressive symptomatology (Kaslow
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& Rehin, 1991). Furthermore, there is some evidence to support the efficacy of activity-

based regimens in adult depressives (e.g., Rehm & Kaslow, 1984).
The relationship between pleasant/unpleasant activities and depression in youth
has been examined empirically. In a sample of 8- to 14-year-old children , Wierzbicki and
Saylor (1991) reported a positive correlation between elevated symptoms of depression
and unpleasant activity levels. However, contrary to the authors ' predictions, they did not
find a negative correlation between self-reported depressive symptomatology and pleasant
activity levels. Although there have not been any depression treatment studies in child
samples that adhere strictly to an activity-increase regimen, several empirical
investigations have used activity-based interventions as part of the treatment protocol
(e.g., Clarke et al., 1995; Kahn, Kehle, Jenson, & Clark, 1990; Lewinsohn , Clarke, Hops,
& Andrews , 1990; Stark, Reynolds , & Kaslow, 1987). As such, it remains unclear as to

whether these activity-based components contribute substantially to treatment efficacy.
Similar to activity-increase regimens that are based on the idea that diminished
reinforcement leads to depressive symptomatology , social skills models are premised
upon the belief that underdeveloped or impaired social skills often preclude individuals
from obtaining adequate social reinforcement that subsequently leads to depression
(Rehin & Kaslow , 1984). Social skills training (SST) has been used to treat depression in
children and adolescents. For example, Fine, Forth, Gilbert, and Haley (1991) compared
a social skills training group and a therapeutic support group in the treatment of
depression in adolescents . The authors reported that the therapeutic support group was
more effective than the social skills group in ameliorating depressive symptoms in the

27
adolescent sample at posttreatment , but that the modalities appeared to be equally
effective after a 9-month follow-up.
In another study, King and Kirschenbaum ( 1990) reported that social skills
training plus consultation was superior to consultation only in the prevention of
depressive symptoms in a cohort of "at-risk " children between 5 and 11 years old .
Furthermore , a number of other treatment studies involving depressed children and
adolescents have included SST components in the intervention protocols (e.g., Clarke et
al., 1995; Kahn et al., 1990; Lewinsohn et al., 1990; Liddle & Spence, 1990; Reynolds &
Coats , 1986; Stark et al., 1987). However , questions remain about the degree to which
social skills training components impact treatment outcomes .
Other types of psychosocial interventions have been used in the treatment of
child and adolescent depression including: aerobic exercise (Brown , Welsh , Labbe ,
Vitulli , & Kulkarni , 1992), relaxation (Kahn et al., 1990; Reynolds & Coats , 1986; Wood
et al., 1996), psychoeducation (Clarke , Hawkins , Murphy , & Sheeber , 1993), and a
combination of group and family therapy (Curry & Wells, 1998). The results from these
studies have been mixed , with substantial differences in methodolog y, selection , and
treatment procedures . Furthermore , Mufson et al. (1994) reported that a variant of IPT
was efficacious in the treatment of early-onset major depressive disorder in a cohort of
depressed adolescents .
Perhaps the most common method of treating depressed youth in empirical trials
is CBT , with the majority of studies favoring group over individual interventions. As
mentioned above , cognitive-behavioral treatments are aimed at identifying irrational and
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dysfunctional thoughts, enhancing awareness of how such thoughts lead to depressive
feelings and behavior, and modifying thinking and behavioral patterns (Beck et al., 1979).
In what is considered by many to be the seminal empirical study on the treatment of
depressed youth, Butler, Miezitis, Friedman, and Cole ( 1980) compared role-play therapy,
cognitive restructuring, and a wait-list control condition in a school-based sample of 56
depressed children. The authors reported that both treatments were more effective in
reducing depressive symptomatology than the wait-list control condition, with role-play
therapy being slightly superior to cognitive restructuring.
In another investigation, Reynolds and Coats (1986) conducted a group treatment
study of child and adolescent depression with 30 moderately to severely depressed high
school students. The investigators compared three treatment conditions including CBT,
relaxation training, and a wait-list control group and reported that both active treatments
resulted in significant improvements in depressive symptomatology when compared to
wait-list controls at posttreatment and after a 5-week follow-up (Reynolds & Coats,
1986).
Furthermore, Weisz, Thurber, Sweeney, Proffitt, and LeGagnoux (1997)
implemented a group-based, eight-session Primary and Secondary Control Enhancement
Training program (see Rothbaum, Weisz, & Snyder, 1982 for further review) with 48
children with mild-to-moderate depressive symptoms. Weisz et al. (1997) reported that
the intervention was effective in reducing self-reported symptomatology at posttreatment
and after a 9-month follow-up in comparison to control subjects. In addition, there is a
recent trend of examining the efficacy of individual CBT in the treatment of depressed

29
youth with some promising results (e.g., Brent et al., 1997; Vostanis , Feehan, Grattan, &
Bickerton, 1996; Wood et al., 1996).
While the aforementioned studies provide us with important insights about the
treatment of childhood depression, many questions are left unanswered. Based upon a
general review of the literature, it is estimated that there are approximately 20-25
empirical studies investigating the efficacy of psychosocial treatments for child and
adolescent depression to date . However, there are important differences across the
various studies (e.g., design , selection, outcome , number of subjects, setting ,
assessment/diagnostic strategies, therapist variables , age range, demographics , type ,
length, frequency , and intensity of treatment) . Thus, useful generalizations about which
interventions would be the most effective and for whom are difficult to make based on a
general review of the literature . These findings highlight the need to integrate the body of
literature on the psychosocial treatments for childhood depression .

Narrative Reviews
Thus far, most of the efforts to review , integrate , and summarize the results of
various psychosocial treatment outcome studies for child and adolescent depression have
been inadequate for guiding research , polic y, and practice because many of the reviews
are narrative in nature , methodologically flawed, and/or present vague or conflicting
conclusions. Thirteen narrative reviews were located, published between 1983 and 1998
(Birmaher, Ryan, Williamson, Brent, & Kaufman , 1996a, 1996b; Clarizio , 1986; Cytryn
& McKnew, 1985; Dujovne, 1993; Harrington , 1992; Holmes & Wagner, 1992; Kashani
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& Cantwell, 1983; Kaslow & Thompson, 1998; Keller , Lavori, Beardslee, Wunder , &

Ryan, 1991; Larsson, 1992; Petersen et al., 1993; Puig-Antich & Weston, 1983;
Reynolds, 1990). The number of psychosocial treatment studies cited in the above
mentioned reviews ranged from zero (Cytryn & McKnew , 1985) to 14 (Kaslow &
Thompson, 1998). In terms of the substantive findings from the earlier reviews , they are
often unclear and conflicting. For example, Clarizio (1986) provided a narrative review
of the treatments for childhood depression, including behavioral regimens , cognitive
strategies , pharrnacotherapy , family therapy, and multimodal therapy . In general , Clarizio
suggested that there is evidence that many of these regimens are effective in ameliorating
depressive symptomatology in children . However , Clarizio (1986) cited only s treatment
studies in his review , he did not include any effect sizes , and he cautioned that "there are
no easy answers " when choosing a treatment method for childhood depression.
In another narrative review , Larsson (1992) concluded that "controlled
investigations of psychological treatments have, to date , been carried out solely with
school samples of children that suffer from moderate depression" (p. 12). Larsson cited
seven treatment studies and he added that most of these treatments were based on
cognitive-behavioral principles (e.g., problem-solving , cognitive-restructuring). In
addition , Larsson reported that despite the evidence that cognitive-behavioral
interventions have been shown to be efficacious with school samples, investigations on
the effectiveness of psychotherapy for depressed children from clinical populations are
nonexistent.
In more recent reviews of the treatments for child and adolescent depression , the
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conclusions are neither compelling nor are they based on exhaustive surveys of the
literature. Dujovne, Barnard, and Rapoff (1995) included approximately treatment
studies in their review and concluded that "the efficacy of cognitive-behavioral treatments
has not yet been consistently demonstrated because investigations have been sparse and
lacking in methods of subject selection and assessment which could result in
representative samples" (p. 606). Approximately one year later, Birmaher et al. (1996a)
reviewed the previous years of literature on child and adolescent depression . While the
authors cited more psychological treatments studies (i.e., 10) than previous reviewers, the
survey was far from comprehensive and the authors did not systematically analyze how
treatment outcomes might covary with important variables (e.g., age, sex, severity of
illness, treatment type).
In perhaps the most systematic narrative review to date, Kaslow and Thompson
(1998) reviewed 14 psychosocial interventions for child and adolescent depression. In
general, the authors suggested that "psychosocial interventions are effective at
posttreatment and follow-up in reducing depressive symptoms/disorders in clinical and
nonclinical samples of youth, regardless of treatment modality or extent of parental
involvement" (p. 146). However, Kaslow and Thompson (1998) examined the extent to
which each of the studies conformed to guidelines proposed by the Task Force on
Promotion and Dissemination of Psychological Procedures ( 1995) "for well-established
and probably efficacious interventions" (p. 146). Briefly, the criteria for well-established
psychosocial interventions for childhood disorders are: (a) at least two well-conducted
group-design studies conducted by different research teams indicate the treatment is
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superior to a pill placebo or an alternative treatment, or equivalent to an already
established treatment; or (b) a large series of methodologically sound single case studies
(i.e. , n > 9); (c) interventions where treatment manuals were utilized; and (d) clearly
specified sample characteristics (Lonigan , Elbert , & Johnson , 1998). The criteria for
probably efficacious psychosocial interventions for childhood disorders are slightly less
stringent in that they do not require replication by two different research teams, the
treatment must be more effective for experimental versus no-treatment control subjects ,
and the required number of methodologically sound single case designs was reduced (i.e.,

n > 3). In sum , Kaslow and Thompson (1998) concluded that only 2 of the 14 studies
reviewed met the criteria for probabl y efficacious psychosocial interventions for
childhood disorders (i.e., Stark et al., 1987; Stark, Rouse , & Livingston , 1991). In
addition , the authors reported that not one of the reviewed studies met criteria for wellestablished psychosocial interventions for childhood disorders . Thus , even the most
recent reviews of the child and adolescent depression treatment literature leave many
questions unanswered and unaddressed.
In summary , published narrative reviews of the child and adolescent depression
treatment literature are plentiful yet uncompelling in guiding policy , research, and
practice . Further , in the reviews published to date, there has not been an attempt to
collect and systematically compare a more comprehensive sample of treatment studies,
including pharmacologic interventions. Thus, a more complete , systematic analysis of the
child and adolescent depression treatment literature is clearly indicated .
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Pharmacological Treatment
The prescription of pharmacologic medications for depression in children has
become a widely accepted practice (Kaplan, Simms, & Busner, 1994) despite the fact that
the Food and Drug Administration (1994; FDA) has yet to approve a single psychotropic
agent for the specific purpose of treating depressed youth up to the age of 17 years old
(Physician's Desk Reference, 1998; Peter Jensen, personal communication, March 16,
1998; Sommers-Flanagan & Sommers-Flanagan, 1996). The practice of using approved
drugs for unlabeled conditions is common and does not prohibit physicians from such
practices (American Academy of Pediatrics Committee on Drugs, 1996). Unapproved
use of approved drugs does not necessarily imply disapproval or contraindication, only
that the drug has not been studied adequately for a particular (i.e., unlabeled) condition.
Before a drug can be approved for a specific problem, its safety and efficacy must be
evaluated and the data submitted to the FDA. Realistically, this process can take several
years, and thus physicians are often faced with challenge of balancing their clinical
judgment with the available empirical literature at the time. The labeling of drugs "is
intended neither to preclude the physician from using his or her best medical judgment in
the interest of patients nor to impose liability for failure to comply with labeling
restrictions" (American Academy of Pediatrics, 1996, p. 144).
In cases of "off label" prescribing, Spencer, Wilens, and Biederman (1995)
suggested that the "risks, potential benefits, and informed consent should be carefully
documented" (p. 97). Thus, a drug's efficacy and its potential side effects must be
carefully evaluated and reviewed with patients and their families before initiating a
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medication trial. In the case of pharmacotherapy for child and adolescent depressive
disorders, psychiatrists and pediatricians can choose from a variety of psychotropic
medications including tricyclic antidepressants (TCAs) such as imipramine (Tofranil),
amitriptyline (Elavil), desipramine (Norpramin), and selective serotonin reuptake
inhibitors (SSRis) including fluoxetine (Prozac), paroxetine (Paxil), and sertraline
(Zoloft). Other medications that have been prescribed for children and adolescents who
present with atypical depression, treatment-resistant mood disorders, and bipolar forms of
affective illness include monoamine oxidase inhibitors, mood stabilizers such as lithium
or valproic acid, and anticonvulsants such as carbamezapine (Spencer et al., 1995).
However, the types of psychotropic medications used most often for children who present
with depression are TCAs and SSRis (Birmaher et al. 1996).
It has been hypothesized that medications such as TCAs and SSRis act on the

noradrenergic and serotonergic systems in the central nervous system by slowing the
reuptake of particular neurotransmitters (e.g., norepinephrine, serotonin) in the synaptic
cleft, thus prolonging postsynaptic potentials (Kandel, 1991). Although several
hypotheses regarding the action of antidepressant medications have been advanced over
the past 30 years (e.g., catecholamine hypothesis), a compelling model of the exact nature
of the pharmacologic mechanisms and the pathophysiology of depression remains elusive
(Duman, Heninger, & Nestler, 1997). Recent empirical findings suggest that
antidepressant medications impact brain physiology well beyond the neurotransmitter
(i.e., monoamine) and receptor levels. For example, Duman et al. (1997) suggested that
the "long-term, therapeutic action of antidepressant treatments is mediated by
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postreceptor intracellular targets" (p. 598; see Duman et al., 1997 for a review).
With regard to the safety of pharmacotherapy for child and adolescent depression,
the potential adverse impact that pharmacologic interventions have on child development
remains unclear (Antonuccio, Danton, & DeNelsky, 1995; Vitiello & Jensen, 1997).
Further, there have been some serious concerns raised about treating children with TCAs.
For example, Riddle, Geller, and Ryan (1993) reported that the sudden death of a child
was associated with the cardiotoxic effects of the antidepressant medication desipramine.
In addition, Werry (1995) seriously challenged the safety of using certain TCAs with
children in light of their noxious side effects (e.g., anticholinergic effects, sedation), and
the increasing number of deaths associated with the use of certain TCAs in children.
However, some authors have suggested that the association between TCAs and
cardiotoxic effects in children remains unclear and should not necessarily preclude their
use in juvenile patients (Wilens et al., 1996). With the advent of SSRis, which are known
to have less noxious side effect profiles (e.g., limited anticholinergic and sedative effects)
and are easier to administer (i.e., once per day) than most of the TCAs, using SSRis might
be a safer alternative to the use of TCAs for the treatment of child depressive disorders
(Birmaher et al., l 996a).
As mentioned previously, the practice of child and adolescent pharmacotherapy
for depression makes sense in light of the strong parallels (i.e., syndromally and
diagnostically) between child and adult manifestations of depressive sequelae (Ryan et
al., 1987) and the empirical evidence that the use of psychotropic medications in adults
suffering from depression is efficacious, with an average positive response rate between
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65% and 75% (Speier et al., 1995; Thase & Kupfer, 1996). In a recent revision of the
FDA regulations (1994) regarding the establishment of efficacy for "pediatric use" of
pharrnacologic agents , it was noted that extrapolations of drug efficacy from adults to
children are justified provided that there is compelling evidence that "the course of the
disease and the drug ' s effects are sufficiently similar in the pediatric and adult
populations " (p. 64241 ). While there is evidence of psychopathological congruity
between child and adult depressive disorders , Vitiello and Jensen (1997) cautioned that
"similar treatment response cannot be inferred across the age groups based only on
similar psychopathological or biological features" (p. 872). The authors added that
despite the similarities in depressi ve phenomenology across the age groups , a
"discrepanc y remains between the efficacy of tricyclic antidepressants in adults versus
that in children" (p. 872, Vitiello & Jensen , 1997).
Despite the equivocal status of treating child and adolescent depression with
TCAs , early studies on the efficacy of antidepressant medication in child and adolescent
samples appeared to be promising . Weinberg et al. initiated an open medication trial for
34 depressed children , using either one of two TCAs , imipramine or amitriptyline
(Weinberg , Rutman , Sullivan , Penick , & Dietz , 1973). The authors reported that 12 of
the 19 children who received the medication evidenced "marked improvement " after one
month. In contrast , it was reported that only 3 of the 15 children who did not receive the
antidepressant medication evidenced clinical improvement after one month (Weinberg et
al., 1973). In another open trial , Puig-Antich , Blau, Marx , Greenhill, and Chambers,
(1978) reported that six out of eight children evidenced a substantial reduction in
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depressive symptomatology after eight weeks of treatment on imipramine.
Other open medication trials appeared to be effective in ameliorating depressive
symptoms in children as well (e.g., Geller, Cooper, Chestnut, Anker, & Shuchter, 1986;
Preskom, Weller, & Weller, 1982). However, as mentioned, these studies were open
trials without control groups, double-blind conditions, or pharmacologically inert
placebos. Thus, the positive findings were questioned on empirical grounds. That is, it
was difficult to determine whether the observed improvements in the children were due to
patient expectations (i.e., "placebo-effects"), measurement error, researcher bias, the mere
passage of time, or other artifactual confounds . Placebo-controlled trials are of particular
interest since a placebo effect is defined as "a beneficial effect. .. that arises from the
patient's expectations concerning the treatment rather than from the treatment itself'
(Stedman's Medical Dictionary, 1995, p. 644). In antidepressant trials for adult samples,
Morris and Beck (1974) reported that the placebo response rates ranged between 30% and
35%, which is generally considered to be an average placebo effect for antidepressants
(Burke & Preskom, 1995).
In light of the aforementioned methodological criticisms of open studies, a
number of randomized, placebo-controlled medication trials for child and adolescent
depression were designed and implemented. For example, Puig-Antich et al. initiated a
placebo-controlled imipramine trial in a sample of 42 depressed children between the
ages of 6- and 12-years-old (Puig-Antich et al., 1978). The authors reported a higher
response in the placebo condition (68%) than in the active medication condition (56%).
These findings were somewhat troubling since they contradicted the previous "evidence"
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of antidepressant efficacy in children reported from the open trials. Kye and Ryan (1995)
reviewed nine randomized, double-blind, placebo-controlled antidepressant trials in child
and adolescent samples. The authors reported that only one study (i.e., Preskorn, Weller,
Hughes, Weller, & Bolte, 1987) provided evidence that pharmacotherapy was superior to
placebo in ameliorating depressive symptomatology in a group of 22 children between the
ages of 6 and 12 years old. Further, Kye and Ryan (1995) cautioned that the evidence of
efficacy in the study by Preskorn et al. was "clinically small but statistically significant"
(p. 268). Preskorn et al. (1987) reported that the improvement from baseline was 43% in
the active medication condition and 35% in the placebo condition.
Only one published meta-analytic study was located in which the placebocontrolled, double-blind trials using TCAs in the treatment of depression in children and
adolescents were reviewed. Hazell, O'Connell, Heathcote, Robertson, and Henry (1995)
reviewed 12 randomized, controlled trials comparing the efficacy of TCAs and placebo in
depressed children between 6 and 18 years of age. The authors reported a standard mean
difference ES of 0.35 for the active medication conditions versus the placebo (control)
conditions. Hazell et al. (1995) concluded that "the small additional effect afforded by
treatment in comparison with placebo is unlikely to be clinically important in most
patients" (p. 899). However, according to the authors, they were only able to derive
effect sizes from 6 of the 12 studies due to limited information contained in the articles.
Thus, some authors have criticized the conclusions from this meta-analytic review on
empirical grounds (e.g., Anderson, 1995). Furthermore, in a review of the drug trials for
early-onset depression, Conners (1992) cautioned that "various methodological problems
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limit the conclusions that can be drawn" regarding the efficacy of antidepressant
medications (p. 11). That is, the substantial differences in the measurements used,
criteria for "improvement," selection procedures, and sample characteristics in the
various studies render comparisons across the studies tenuous at best (Conners, 1992).
Although the literature regarding the use of TCAs in the treatment of child and
adolescent depression has been either discouraging or equivocal, there have been several
recent studies involving the use of SSRis with promising results. In a retrospective
review of the medical records of 31 children between 9 and 18 years old who were
hospitalized for depression, Jain, Birmaher, Garcia, Al-Shabbout , and Ryan (1992)
reported that after a mean treatment duration of 35 days on fluoxetine, clinical
improvement was seen in 74% of the patients as measured by the Clinical Global
Impression Scale. In another retrospective review, Tierney, Joshi , Llinas, and Rosenberg
(1995) evaluated the efficacy of sertraline in a group of 33 children and adolescents
between the ages of 8 and 18 years old . The authors reported that the majority of the
children evidenced significant improvement based on the indices of Clinical Global
Impression Scales after the 10th week of treatment (Tierney et al., 1995). Moreover,
open trials with fluoxetine have reportedly produced a significant reduction of depressive
symptomatology in child and adolescent patients as well (e.g., Boulos, Kutcher, Gardner,
& Young, 1992; Collie, Belair, Difeo, Weiss, & LaRoache, 1994).

In addition to retrospective reviews and open trials, the results from several
controlled studies involving the use of SSRis in child and adolescent samples have been
published recently. Simeon, Dinicola, Ferguson, and Copping (1990) conducted a study
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in which 40 adolescents between 13 and 18 years old participated in a placebo-controlled,
double-blind study of fluoxetine treatment for depression. The authors reported that
"fluoxetine was superior to placebo on all clinical measures except for sleep disorder, but
the differences were not statistically significant" (Simeon et al., 1990, p. 71). In another
trial, Mandoki, Tapia, Tapia, and Sumner (1997) evaluated the efficacy of venlafaxine
(Effexor) in a cohort of 33 children and adolescents who met the DSM-IV (APA, 1994)
criteria for major depressive disorder. The two treatment conditions consisted of
venlafaxine and psychotherapy or placebo and psychotherapy. The authors reported that
significant improvements were observed in both conditions, but they were reluctant to
attribute the positive effects to venlafaxine drug therapy (Mandoki et al., 1997).
However, in a recently published controlled trial of 96 children and adolescents being
treated with fluoxetine , Emslieet al. (1997) reported a positive response rate of 56% in the
active condition compared to a 33% positive response rate for those taking placebo.
Thus, it appears that there have been some recent positive findings regarding the efficacy
of SSRis in children and adolescents with depressive disorders.
Overall, it is estimated that there are between 14-17 published studies
investigating the efficacy of psychotropic medications for depressed youth. A more upto-date comprehensive review that integrates the recent studies and includes a systematic
analysis of some of the important variables associated with outcome (e.g., length of
treatment, outcome measures) might provide some answers to important questions related
to the efficacy of pharmacotherapy for child and adolescent depression. Furthermore,
there is a paucity of data on the comparison of pharmacological and psychosocial
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interventions for depressed children and adolescents. Only two studies were located that
compared psychotherapy versus pharmacotherapy in the treatment of early-onset
depression. In one of the studies (Mandoki et al., 1997, cited above), a sample of
adolescents with major depression were treated with either venlafaxine and
psychotherapy or pill placebo and psychotherapy. Although both treatments appeared to
ameliorate depressive symptoms to a substantial degree, Mandoki et al. ( 1997) reported
that "there was not a significant difference in improvement between both groups, which
indicates that the medication treatment did not contribute significantly to the
improvement" (p. 153). In the only other study located that compared psychosocial and
pharmacological interventions , Dujovne (1993) treated six clinically depressed children
between the ages of 8 and 11 with imipramine and cognitive-behavioral therapy in a
multiple-baseline, crossover design. Dujovne (1993) reported that both treatments
resulted in a significant reduction in depressive symptoms over the course of the study
with a slight advantage to the cognitive-behavioral regimen and increased parental
satisfaction of the nonpharmacologic intervention (i.e., cognitive-behavioral therapy).
However, the author cautioned that four of the six children evidenced noxious sideeffects while taking the imipramine and the medication was discontinued. In sum, it
appears that there are some important questions to be answered regarding the comparison
of psychosocial and pharmacological interventions for depressed youth. The most
compelling question seems to be whether pharmacotherapy should be the first-line
treatment for children and adolescents who present with depression when
nonpharmacologic interventions may be just as effective and do not expose the patient to
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potentially noxious, if not dangerous side-effects.

Summary
In summary, a number of treatments for childhood depressive disorders have been
developed ranging from pharmacotherapy to psychosocial regimens and it is estimated
that there are approximately 40-50 studies investigating the efficacy of interventions for
depressed youth. What we do know about the efficacy of psychosocial treatments for
childhood depression is limited. There is moderate support for the efficacy of schoolbased group interventions for children and adolescents who evidence depressive
symptomatology on self-report measures . However, beyond this, there is not much else
that can be said about empirically validated psychosocial interventions for childhood
depression . In terms of pharmacologic interventions , it appears that TCAs have not been
found to be superior to placebo in the majority of controlled outcome studies. There have
been some recent studies of the efficacy of TCAs and SSRis in the treatment of children
with depression, but these findings have yet to be integrated into a comprehensive
literature review. Although some of the efforts to review and synthesize the body of
literature on the treatments for depressed youth have answered some questions , there are
many more questions left unanswered. For instance, which variables need to be
considered? Do outcomes covary with study and sample characteristics? Which types of
treatments are the best and for whom? Does the length of treatment impact outcomes?
Does the age of the child matter? Do comorbid conditions impact the outcomes? Does it
make a difference whether the children have been identified as suffering from depressive
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symptomatology as opposed to a depressive disorder? Are the findings from a schoolbased sample generalizable to a clinic-based sample?
If a comprehensive, methodologically sound review of the literature on the

efficacy of psychosocial and pharmacological treatments for childhood depression
existed, researchers and clinicians would have a better understanding of which treatments
are effective in ameliorating depressive symptomatology in children as well as how
outcomes covary with study and sample characteristics. Furthermore, a good integrative
review would help to guide both intervention efforts and future empirical studies on the
treatment of depressive disorders in children.

Treatment Variables

As mentioned previously, there are several variables that must be considered
when evaluating whether treatments for depression are effective for children. Central to
question of treatment effectiveness is: What treatments are effective for whom and under
what conditions? Ultimately , clients are best served when there is a proper fit between
the client, the therapist, and the intervention. For example , if an 11-year-old, moderately
depressed boy presents for treatment, what is the recommended course of treatment?
Based on some of the empirical findings , one might recommend a school-based group
intervention such as the Primary and Secondary Control Enhancement training proposed
by Weisz et al. (1997) . Further, it could be argued that a prerequisite client variable for
this type of treatment is an adequate level of intellectual functioning in light of the
cognitive underpinnings of Primary and Secondary Control Enhancement training.
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However, suppose the child is cognitively impaired, thus precluding him from
participating effectively during the treatment group? What if the child were an 8-yearold, severely depressed female youngster? In other words, what can we say about the
differential effectiveness of various treatments in light of some of these important
variables?
Because a major thrust of this investigation is based upon how treatment study
variables moderate outcome, several important variables will be defined and described in
the following section, including age, sex, referral source, treatment setting, type of
treatment, treatment variables, assessment measures, therapist variables, severity of
illness, and comorbid conditions. In addition, available information on how the
aforementioned variables impact treatment outcomes will be reviewed

An important variable to consider when selecting the best course of treatment for

depression is the client's age. As mentioned previously, certain therapies might be
inappropriate for very young children such as certain cognitive regimens that might
presuppose a particular level of cognitive development (e.g., formal operations, Piaget &
lnhelder, 1969). No published studies were located that addressed specifically, the
potential interaction between age and the treatment of early-onset depression (i.e.,
adolescent vs. child samples). Yet some interventions target one age group or another
(e.g., Coping with Depression Course for Adolescents; Clarke, Lewinsohn, & Hops,
1990). In addition, the empirical findings on the relationship between a child's age and
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general psychotherapy outcome have been equivocal. For example, Weisz et al. (1987)
conducted a meta-analysis of 108 treatment studies regarding the overall effectiveness of
psychotherapy with children and adolescents. The authors reported that "therapy proved
more effective for children (ages 4-12) than for adolescents (ages 13-18)" (p. 542).
Weisz et al. reported that the mean effect size for therapy involving children was 0.92 as
compared to 0.58 for adolescent clients.
In contrast, Weisz, Weiss, et al. (1995) completed another integrative review (150
different studies) of the effects of psychotherapy with children and adolescents and
reported that "treatment outcomes were better for adolescents than for children" (p. 461).
For children 11 and younger, the authors reported a mean effect size of 0.48, whereas the
mean effect size was 0.65 for adolescents 12 and older. While it is unclear whether the
differential inclusion criteria (i.e., "children" defined as 4-12 in Weisz et al., 1987 as
compared to 11 and younger in Weisz, Weiss, et al., 1995) impacted the mean effect size
calculations, the differential findings leave many questions unanswered . However ,
Weisz, Weiss, et al. ( 1995) suggested that the changes in age effect might be attributable
to improvements in the effectiveness of adolescent interventions. In any case, the
relationship between age and outcome remains unclear, especially with respect to the
treatment of child and adolescent depression.

The interaction between sex and therapy outcome has been investigated by several
researchers who have conducted large meta-analytic reviews (e.g., Casey & Berman,
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1985; Weisz, Weiss, et al., 1995). Taken together, the findings suggest that
psychotherapy is generally more effective for females than males. Weisz et al. (1987)
reported a mean effect size of 1.11 for female majority groups and 0.80 for male majority
groups. Weisz, Weiss , et al. (1995) reported similar findings , indicating that the mean ES
for female samples was 0.71 as compared to 0.43 for male samples. In addition, the
authors reported an age/sex interaction wherein the mean ES was 0.86 for adolescent
female majority samples as compared to 0.37 for adolescent males. In contrast, the mean
effect sizes for the male and female child samples (i.e., 11 and younger) were
approximately equal. Thus , while there have been some interesting findings to date, more
information is needed to better understand the relationship between sex and depression
treatment outcome.

Referral Source
How a child or adolescent is referred for treatment is an important variable to
consider when evaluating outcome. For example , has the child been clinically referred
for treatment due to presenting symptomatology? Or, has the child been recruited by a
research team and therefore volunteers to participate as an analog subject? Assuming the
treatment is shown to be effective in ameliorating certain symptomatology in volunteer
research subjects , the crucial question is whether the "effectiveness" is generalizable to
actual clinical cases which may be more difficult to treat successfully. Weisz , Donenberg,
Han, and Kauneckis (1995) reported that
it is certainly possible that clinic-referred children are more seriously
disturbed, that they come from more dysfunctional families, or that they
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are more likely to confront stressful life circumstances (e.g., low income
levels) than are the often middle class youngsters whose parents give
consent for their participation in research studies. (p. 96)
Nevertheless , Weisz, Donenberg, et al. (1995) addressed this question empirically
by comparing the mean effect sizes of clinic and analog samples from two large metaanalytic reviews and reported that the differences were not statistically different. Further ,
based on the results from one of the meta-analyses (i.e., Weisz et al., 1987), the mean
effect size of the analog samples (0.76) was smaller than the clinic samples (0.89),
indicating that overall, psychotherapy was slightly more effective in treating clinical
samples . Thus, the findings to date have been inconsistent regarding the impact of
referral source on treatment outcome .

Treatment Setting
The setting in which psychotherapy is conducted is thought to have important
implications for therapy outcome (Brent et al., 1997; Weisz, Weiss, & Donenberg , 1992).
Treatment is conducted in variety of environments including inpatient units (e.g.,
hospitals) , schools , outpatient clinics, private practice, research laboratories , and
correctional settings . Some authors have suggested that treatment delivered during the
course of everyday clinical practice as opposed to research or laboratory settings differs in
important ways (Seligman , 1995). Clarke (1995) outlined a distinction between "efficacy
investigations " and "effectiveness research." According to Clarke, efficacy investigations
are controlled laboratory studies, whereas effectiveness research are clinical studies
carried out in "broader mental health services systems" (p. 718). While Clarke lamented
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how little attention is paid to how the results from controlled clinical trials generalize to
applied clinical settings , some investigators have examined this issue .
Weisz et al. (1992) found evidence that controlled research trials tended to
produce better treatment outcomes than treatment provided in everyday applied clinical
settings . However, the authors cautioned that their findings were based on relatively few
clinic studies and that the studies had some methodological problems in comparison to
the more rigorous and tightly supervised controlled trials. In addition, Kazdin (1990)
suggested that there are major discrepancies between research treatment and clinical
practice which make the extrapolation of the findings from one setting to the other
problematic. According to the authors, the problem of generalizability may be
attributable to factors such as problem foci and the severity of presenting problems.
Further , Kazdin (1990) noted that the majority of treatment studies solicit children from
school settings and provide treatment in groups , whereas clinically referred children in
everyday clinical practice are seen usually on an individual basis.
Furthermore, other investigators have examined whether other variables related to
research and clinical settings had differential effects on therapy outcome. For example ,
Weisz , Donenberg , et al. (1995) questioned whether there is something about clinical
settings that undermine the effectiveness of psychotherapy for children (e.g., heavy
caseloads, not problem-focused, not as strictly supervised). The authors found evidence
that three factors contributed to the "superior" findings found in analog studies including:
(a) the prevalent use of behavioral and cognitive-behavioral methods; (b) a reliance on
focused, specific therapy techniques; and (c) the provision of structured supervision and
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monitoring (e.g., protocol adherence, reliability checks) throughout the trial.
In sum, it appears that certain aspects of the treatment setting have the potential to
moderate outcome based on general reviews of the child and adolescent psychotherapy
literature. However , it remains to be seen whether some of the aforementioned issues
have an impact on interventions for child and adolescent depression.

Type of Treatment
A major thrust of this investigation focuses on the relative effectiveness of various
treatments for childhood depression. As mentioned previously, several treatments have
been developed and implemented for childhood depression including but not limited to
psychodynamic , cognitive-beha vioral, behavioral , problem-solving, relaxation , social
skills training , activity-based , self-control training , interpersonal psychotherap y, family
therapy , and pharmacotherap y. However, it appears that no single treatment is clearly
superior to the others in ameliorating depre ssive symptomatolog y in children . In
addition , there are those who suggest that most treatments are virtually equivalent in
terms of therapeutic benefit. For example , Rehm (1995) suggested that we abandon the
"horse race" comparisons between treatments for depression in adults in light of the fact
"that comparison between any two such programs is unlikely to produce important
differences in effectiveness" (p. 203) . In evaluating the overall effectiveness of
psychotherapy , the equivalency of outcome from a variety of treatment methods has been
referred to as the "dodo verdict" (Parloff, 1984). While there is some support for the
dodo verdict in terms of the efficacy of various forms of psychotherapy for adult
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depression and other disorders (e.g., Robinson et al., 1990; Smith, Glass, & Miller, 1980),
it remains unclear whether this so-called dodo verdict is applicable to psychotherapy for
child and adolescent depression.
For example, three large meta-analytic reviews provided some support for the
idea that behavioral treatments are more effective than nonbehavioral methods in treating
a variety of child and adolescent psychopathology (Casey & Berman, 1985; Weisz et al.,
1987; Weisz, Weiss, et al., 1995). However, the issue is far from settled as some authors
have suggested that the differential effects are attributable to artifactual explanations such
as methodological differences between studies (e.g., Shirk & Russell, 1992). However ,
Weiss and Weisz (1995) reported that there was "little support" for such a hypothesis. In
any case, there is empirical evidence to justify the comparison of various treatments for
child and adolescent problems in light of the aforementioned findings. Further , little is
known about the differences between behavioral versus nonbehavioral treatments for
childhood depression in particular and how these variables interact with factors (e.g., agerelated developmental changes) .

Other Treatment Variables
The actual length (i.e., weeks) and frequency (i.e., number of sessions) are
important variables to consider when evaluating treatment outcome. An intuitively held
assumption in psychotherapy research is that "more therapy is better." Historically, this
assumption has played out in professional practice as the average duration of treatment in
clinical settings (27-55 weeks) is substantially longer than it is in research or laboratory
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settings (8-10 weeks; cf. Kazdin et al., 1990). However, in light of the present political
and financial climate (i.e., cost containment, managed care), the need for empirically
validated yet brief interventions for various psychological problems has never been
stronger (Weisz et al., 1997). Furthermore, the intuitive assumption that more therapy is
better has not been empirically supported (Weisz, Donenberg , et al., 1995). In light of the
limited data on this issue, there is a need to better understand the relationship between
various treatment variables (e.g., length , frequency) and the effectiveness of treatment for
child and adolescent depression (Clarke, 1995).

Assessment Measures
As mentioned previously , the process of assessment can have a significant impact
on treatment outcome studies because the assessment and diagnosti c measur es that guide
the inclusion and evaluation of subjects are used to determine whether the treatment is
efficacious or not. There are a number of methods for assessing depression in youth
including : behavioral observations , behavior rating scales (e.g., Child Behavior Checklist
CBCL ; Achenbach & Edelbrock , 1983), sociometric approaches , diagnostic interviews ,
and self-report measures , the latter two of which are the most prominent. Several
excellent self-report measures have been developed such as: the Children's Depression
Inventory (CDI; Kovacs, 1992), the Mood and Feelings Questionnaire (MFQ ; Angold ,
Costello, Pickles , & Winder, 1987), the Reynolds Child Depression Scale (RCDS;
Reynolds , 1989), the Center for Epidemiological Studies - Depression Scale (CES-D;
Radloff, 1977), the Reynolds Adolescent Depression Scale (RADS; Reynolds, 1987), and
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the Beck Depression Inventory (BDI ; Beck & Steer, 1987). Some of the more prominent
diagnostic interviewing formats include the Schedule for Affective Disorders and
Schizophrenia for School-Aged Children (K-SADS; Puig-Antich & Chambers , 1978) , the
Children ' s Depression Rating Scale (CDRS ; Poznanski & Mokros , 1996), the Bellevue
Index of Depression (BID ; Petti , 1978), and the Diagnostic Interview for Children and
Adolescents-Revised (DICA-R; Reich & Welner, 1988).
Nonetheless , many investigators (e.g., La Greca , 1990) have stressed the
importance of a multimethod protocol in light of the limitations of any one particular
measure. At the same time , this process is often more the exception than the rule , and
there has been a historical overreliance on a limited number of devices to evaluate
depression treatment efficacy. For example , Black-Cecchini ( 1996) reported that of the
13 treatment studies reviewed , 5 studies relied exclusively on one self-report device to
determine efficac y . Further , of the 8 studies that used interview formats , sufficient data
to calculate effect sizes were available in only 4 of the studies .
Similarly , there is empirical evidence that depressive symptomatology , as
measured by self-report instruments , attenuates over time , and repeated administrations
(e.g ., Finch , Saylor , Edwards , & Mcintosh , 1987; Michael & Merrell , 1998). This
attenuation phenomenon has been interpreted in several ways including: (a) an overendorsement of symptomatology by distressed children upon initial testing (Reynolds,
1986); (b) an expected variation in reported symptomatology due to natural fluctuations
in mood over time (Kovacs , 1992); and/or (c) a better understanding of the assessment
task during subsequent intervals (Michael & Merrell , 1998).
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In sum, it is vital to consider the impact that the measurement technology has
upon the determination of treatment efficacy in light of the aforementioned data. While it
seems apparent that there is a significant relationship between assessment and treatment
outcome, there is a need to examine this relationship in-depth.

Therapist Variables
Therapist variables such as level of training, years of experience , and professional
discipline have long been considered important when evaluating therapy outcome
(Kazdin et al., 1990; Stein & Lambert, 1984). For example, Weisz et al. (1987) reported
a significant interaction between level of training and client age, with paraprofessionals
and graduate students being more effective with children as opposed to adolescent clients.
In contrast, profes sional therapists were equally effective with both groups (Weisz et al.,
1987). In addition , Weisz et al. reported that professional therapists were somewhat more
effective than their less trained counterparts (i.e., graduate students , paraprofessionals)
with "overcontrolled " problems such as phobias and shyness. In a more recent
investigation , Stein and Lambert (1995) conducted a meta-analysis of outcome studies
involving within-study comparisons of therapists with different levels of training and
experience . The authors concluded that "a variety of outcome sources are associated with
modest effect sizes favoring more trained therapists" (p. 182). However , both Weisz et
al. and Stein et al. cautioned that it is markedly difficult to come up with an accurate
coding scheme to account for all the variables associated with differential training levels
across a diverse array of studies (e.g., graduate students being supervised closely by
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experienced professionals) . Therefore, such methodological problems pose a significant
threat to the validity of these findings. In sum, although there is growing evidence that
increased levels of training are associated with greater levels of improvement, it is
unsettling that "more compelling evidence is not available that demonstrates that graduate
training directly relates to enhanced therapy outcomes" (Stein & Lambert, 1995, p. 194).
Further, despite some provocative findings , it is unclear whether these trends are evident
in the treatment of early-onset depression.

Severity of Illness and Comorbiditv
As mentioned previously, childhood depression is neither a discrete nor a
homogeneous problem . It varies greatly in both the type and severity of symptom
presentation . However , in treatment outcome research , there is usually a specific disorder
or symptom that is identified as the dependent variable targeted for change (Hoagwood ,
Hibbs , Brent , & Jensen , 1995). An important question that needs to be addressed is : Does
the type and severity of symptom presentation affect outcome?
Furthermore , in clinical settings , depression is often only one of many clinical
syndromes (e.g. , anxiety) that may be present in the same individual. A number of
potential treatment subjects are often excluded from empirical studies if they present with
a variety of comorbid conditions or symptoms even though this is common in everyday
clinical settings (Clarke , 1995). These factors can make generalizations from the
empirical literature to clinical practice problematic (Hoagwood et al., 1995). Hoagwood
et al. (1995) suggested that treatment research needs to adapt to the "real life" situations
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that are encountered in clinical practice by considering some of the these important
variables such as comorbidity . In general, it would be important to consider whether
various treatments for depression are impacted by or have an impact upon, comorbid
conditions.

Quality of Study
Various authors have suggested that the quality of a study can impact not only the
findings from a particular study, but also the overall findings from an integration or metaanalytic review of several studies (e.g., Wilson & Rachman, 1983; Wortman, 1983).
Wilson and Rachman (1983) hypothesized that methodologically weaker studies might
skew the results from integrative reviews in the direction of an overestimation of therapy
effects. Some aspects of how methodological variables impact ES calculations were
examined in the one of the seminal meta-analyses of psychotherapy outcome (Smith et
al., 1980). However , Smith et al. did not find compelling evidence that, for example ,
poor quality studies produced spuriously larger effect sizes in comparison with more
methodologically rigorous studies. With regard to child psychotherapy outcome research
in particular , Weiss and Weisz (1990) examined the results from large meta-analytic
studies to determine whether methodological factors impacted the magnitude of effect
sizes. Weiss and Wiesz focused on factors that might compromise internal and external
validity such as selection bias, subject attrition, random assignment, measurement flaws,
history, therapist variables, and ecological (clinical vs. analog settings) factors (Campbell
& Stanley, 1963). Weiss and Wiesz (1990) reported that
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together , these factors accounted for two-thirds as much variance as the
substantive factors (e.g. , type of therapy , age) in the original metaanalysis ... [and that] in general , increased experimental rigor was related to
larger effect sizes; this argues against the hypothesis that methodologically
weak studies have led to an overestimate of therapy effects. (p . 639)
Nonetheless , the quality of each study included in the present analysis will be coded and
evaluated to examine whether methodological factors impacted treatment outcome .

Summary

In summary , depression in children and adolescents is a recognized phenomenon
that adversely affects the lives of many youth . In light of the prevalence , persistence , and
negative outcomes associated with depressive disorders in children and adolescents ,
several treatments have been developed ranging from psychosocial interventions to
pharmacological interventions. Current reviews of the outcome studi es for child and
adolescent depression have not been adequate for guiding research , policy , and practice
because many of the reviews are narrative in nature , methodologically flawed , and/or
present vague or conflicting conclusions . Furthermore , while some of the efforts to
review and synthesize the body of literature on the treatments for depressed youth have
answered some questions , there are many more questions left unanswered. If a
comprehensive, methodologically sound review of the literature on the efficacy of
psychosocial and pharmacological treatments for childhood depression existed , there
would be a better understanding of which treatments are effective in ameliorating
depressive symptomatology in children as well as how outcomes covary with study and
sample characteristics. Furthermore , a good integrative review would help to guide both
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intervention efforts and future empirical studies on the treatment of depressive disorders
in children.

Purpose and Objectives

The purpose of this research project was to determine the overall efficacy of
psychosocial and pharmacological treatments for child and adolescent depression. An
additional purpose of this inquiry was to examine how certain variables impacted
treatment outcomes (e.g., age, sex, type of treatment, quality of study).
The objectives of this study were as follows:
1. To determine the overall efficacy of psychosocial interventions for child and
adolescent depression .
2. To determine the overall efficacy of pharmacological treatments for child and
adolescent depression.
3. To determine whether there is differential efficacy for psychosocial and
pharmacological treatments when the following 11 variables are considered: (a) age,
(b) sex, (c) referral source, (d) treatment setting, (e) type of treatment, (f) length and
frequency of treatment, (g) assessment measures, (h) therapist variables, (i) severity of
illness, (j) comorbidity, and (k) quality of study.
Given the aforementioned purpose and objectives, the following three research
questions were addressed in this investigation:
1. What is the overall efficacy of psychosocial interventions for child and
adolescent depression?
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2. What is the overall efficacy of pharmacological treatments for child and
adolescent depression?
3. Is there evidence of differential efficacy for psychosocial and pharmacological
treatments when the following 11 variables are considered: (a) age, (b) sex, (c) referral
source, (d) treatment setting , (e) type of treatment , (f) length and frequency of treatment ,
(g) assessment measures , (h) therapist variables, (i) severity of illness, (j) comorbidity,
and (k) quality of study?
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CHAPTER III
METHODOLOGY

Population and Sample

The population for this investigation included empirical studies on the treatment
of child and adolescent depression. The overall sample for this investigation included 37
psychosocial and pharmacological studies targeting child and adolescent depression
published between 1980-1998. There were 23 psychosocial studies (36 separate
treatments) and 14 pharmacological trials. Case reports and single-subject designs were
not included. The articles were located through a comprehensive search strategy
including an extensiv e computer search of databases such as PsycLIT , ERIC, and
Medline . Key words and various combinations were used including : depression ,
depressed , mood , internalizing , child, children, childhood , adolescent , adolescence ,
juvenile , treatment , therapy , psychotherapy , intervention , pharmacotherapy ,
pharmacologic, medication , tricyclic , antidepressant , SSRI, TCA, outcome , and metaanalysis. Hand searches of the reference lists from the obtained articles were conducted
in an effort to find additional articles and several authors were contacted to inquire about
"in press" studies or unpublished manuscripts . Manual searches of a variety of peerreviewed journals were completed as well, including the Journal of Consulting and
Clinical Psychology, the Journal of the American Academy of Child and Adolescent
Psychiatry , Behavior Therapy, Archives of General Psychiatry, School Psychology
Review , Behavioral Psychotherapy, the Journal of Clinical Child Psychology, the Journal
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of Affective Disorders, and the Journal of Child Psychology and Psychiatry.
Finally, a comprehensive search of unpublished theses and dissertations via
ProQuest Dissertation Abstracts was completed dating back to 1980. Fifteen potentially
relevant dissertations were located, of which 10 were ordered. Several of the
dissertations ordered were not received (i.e., four) due to restrictive lending policies at the
various institutions. Of the six dissertations received, two were deemed appropriate for
coding and included in the final sample of studies.
For a study to be included in the investigation , the effects of a particular treatment
on child and adolescent depression had to be examined. The following specific criteria
must have been met as well : (a) the study had to be a within- or between-subjects group
design ; (b) the sample was targeted for intervention based upon "at risk" status (i.e.,
prevention) , presenting depressive symptomatology , or a depressive diagnosis ; (c) the
subjects targeted for intervention were between the ages of 5-18; (d) the treatment was
psychosocial or pharmacolog ical in nature (e.g., group, individual , family, TCA, SSRI) ;
and (e) the study utilized at least one depression outcome measure once the intervention
was completed .

Design

An integrative or meta-analytic design was used during the course of this study ,
whereby the results from related treatment studies can be compared (Glass, 1977). In
conducting a meta-analysis, the investigator codes the findings from empirical studies and
converts them into an effect size, a common metric upon which comparisons across the
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various studies can be made. A commonly used effect size is the standardized mean
difference , that is, the treatment group mean minus control group mean, divided by
control group or pooled standard deviation (Smith et al., 1980).
In terms of what an effect size actually indicates, Cohen (1988) stated that "it is
convenient to use the phrase ' effect size' to mean ' the degree [d] to which the
phenomenon is present in the population,' or ' the degree to which the null hypothesis is
false '" (pp. 9-10) . Effect sizes are typically expressed in standard deviation units (Wolf ,
1986). Thus, if a calculated effect size (d) is expressed as .50, this is interpreted as onehalf of a standard deviation difference between the means of the groups under study (e.g.,
treatment versus control groups), indicating that "33% of the combined area covered by
two normal equal-sized equally varying populations is not overlapped " (Cohen , 1988, p.
26). Furthermore , Cohen offered guidelines to interpret the magnitude of an effect size.
According to Cohen (1988), effect sizes between 0.20 and 0.49 are considered "small ,"
effect sizes between 0.50 and 0.79 are considered "moderate ," and effect sizes 0.80 or
larger have been described as "large." Cohen (1988) suggested that these qualitative
interpretations are somewhat arbitrary and should be made with caution , keeping in mind
the particular variables under study. For example, if one is measuring the outcome of a
blood-pressure reduction treatment wherein the standard deviation is three diastolic
points, an effect size of 2.0 would be a large effect, but arguably clinically meaningless
because the effect size is based upon a mean difference of approximately six diastolic
points . As such, the practical implications of such an effect size are marginal at best.
Thus, the scaling of the outcome measures must carefully considered before interpreting
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the magnitude of effect sizes
In the present study, a meta-analytic design was used because these designs are
often more efficient and effective than narrative reviews in accurately synthesizing large
amounts of data from a number of studies (Glass, McGaw, & Smith, 1981). Wolf(1986)
suggested that some of the common problems associated with narrative reviews can be
addressed by conducting a meta-analysis, including biased selection of studies,
differential weighting of studies, misleading interpretations of study findings, and failure
to examine moderating variables in the questions being addressed. At the same time, it
has been suggested that the standards of methodological rigor in meta-analyses be just as
stringent as empirical studies (Wolf, 1986). For example, Glass et al. (1981) grouped
criticisms of meta-analyses into four domains including: (a) the diversity across studies
(e.g., sample characteristics, measurement technology, treatment variables) makes
comparisons inappropriate; (b) the results from poorly designed studies given equal
weight with well-designed studies skew the results; (c) studies that produce
nonsignificant findings are rarely published, thus creating a biased sample of studies; and
(d) studies given too much weight have multiple results.
The aforementioned criticisms of meta-analytic designs can be addressed in
various ways. For example, when dealing with the diversity and methodological
differences across studies, the researcher is best advised to code certain characteristics
from each study (e.g., treatment type, methodology) and examine whether the variables
mediate the meta-analytic results (Wolf, 1986). As mentioned previously, analyzing how
study characteristics covary with outcomes is a major thrust of the study. Thus, a
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systematic coding system was developed and implemented to examine the relationship
between the 11 broadly construed variables and the treatment outcomes (i.e., ES) .
As described above, Wilson and Rachman (1983) hypothesized that
methodologically weaker studies might skew the results from integrative reviews in the
direction of an overestimation of therapy effects . Thus, in order to account for the
potential problem of giving poorly designed studies equal weight with well-designed
studies, the quality of each study was rated on the basis of two criteria: (a) the potential
threats to internal validity and (b) the overall validity of the study . These criteria were
analyzed to determine whether there were differential outcomes based on study quality.
When dealing with a potentially biased sample of studies, also referred to as the
"file drawer " problem (Rosenthal, 1979), it has been suggested that a more
comprehensive search strategy be employed along with broader inclusion criteria (Glass
et al., 1981). As outlined above, a comprehensive search strategy was employed in the
present study, including a review and solicitation of unpublished manuscripts . Although
the majority of the studies included in the present analysis were published, a moderate
amount of data was included from unpublished manuscripts (e.g., Curry & Wells, 1998)
and dissertations (e.g., Hickman, 1994).
With respect to the unequal weighting of studies problem, some authors have
suggested averaging multiple results from one study to yield perhaps one or two effect
sizes, thus preventing studies with multiple results from having undue influence on the
overall estimate of the effect size across studies (Smith et al., 1980). To address this
issue in the present investigation, a maximum of two effect sizes per treatment modality
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were calculated to prevent unequal weighting of the effects from a particular study with
the potential for multiple effect size calculations.

Instrumentation and Analysis

A comprehensive coding sheet was developed so that each of the treatment
outcome studies was evaluated based on 11 broadly construed variables including: (a)
age, (b) sex, (c) referral source, (d) treatment setting, (e) type of treatment, (t) length and
frequency of treatment, (g) assessment measures, (h) therapist variablesm (i) severity of
illness, (j) comorbidity, and (k) quality of study. The quality of each study was rated
based on: (a) potential threats to internal validity and (b) the overall validity of the study.
Seven potential threats to internal validity were evaluated on a scale of O to 3 (0 = not a
plausible threat; 1 = minor threat; 2 = plausible threat ; 3 = by itself could explain the
findings) . The potential threats included: maturation, history, testing, instrumentation,
regression, selection bias, and experimental mortality. These threats to internal validity
and the associated effects upon treatment outcomes have been described extensively in
the literature (e.g., Borg & Gall, 1989; Campbell & Stanley, 1963). The overall validity
of study was assessed based on several factors including the aforementioned threats to
internal validity, sample size, selection procedures, methodological rigor, and
measurement technology. A 5-point Likert scale (5 = excellent; 4 = good; 3 = fair; 2 =
inferior; 1 = unacceptable) was used to evaluate each study.
Each study was double-coded by the primary researcher and a second Ph.D.
candidate in psychology with extensive experience in coding studies for meta-analytic
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designs. The second coder was trained in the specific procedures outlined in this study,
and interrater reliability coefficients were calculated for each variable coded. Two
formulas were used to calculate the interrater agreement. First, interrater reliability was
calculated by dividing the total number of congruent observations (CO) by the total
number of observations (TO) and multiplied by 100. Second, Cohen ' s Kappa (Cohen ,
1960) was calculated for each variable to compensate for the limitations in the first
formula since the procedure is used to determine agreement beyond chance levels. After
calculating reliability data, disagreements in the coding of certain variables were
reconciled through consultation and clarification among the coders. A copy of the coding
sheet is included in the Appendix.
The results and variables from the various treatment studies were analyzed by
computing a number of effect sizes. Effect sizes were calculated with the assistance of
the DST AT computer software program (Johnson, 1989) whereby the outcome data (i.e.,
means , standard deviations , sample sizes) were entered . In cases where the means and
standard deviations were not provided, effect sizes were computed from other data
reported in the studies (e.g., f-ratios or !-statistics). Furthermore , in a large number of
pharmacologic studies means , standard deviations, f-ratios , or !-statistics were not
reported. Instead, the percentage of improvement in the treatment and placebo-control
groups was reported . Treatment response in these studies was determined by whether the
subjects met criteria for "improvement " (i.e., change observed on particular measures).
However, the criteria for improvement and the measures utilized to determine change
varied across the studies. Nonetheless, effect size estimates were calculated by
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transforming the difference in proportions (percent improved) between the experimental
and placebo-control group subjects. This procedure (probit transformation) has been used
in a number of meta-analyses (e.g., Clum, Clum, & Surls, 1993; Miller, 1977) and is
described elsewhere (see Smith et al., 1980).
Although this procedure is far from ideal in calculating ES, it is more effective
and accurate than simply excluding the study from the analysis. One of the primary
limitations of this procedure is the inevitable loss of information that takes place after the
outcome data are transformed multiple times into an effect size. Nonetheless, it addresses
a criticism (Anderson, 1995) of a previous meta-analysis (Hazell et al., 1995) on the
efficacy of using antidepressant medications in children and adolescents whereby effect
sizes were calculated from only 6 of the 12 studies due to the limited data contained in
the articles . For studies that did not report any data suitable for conversion to effect sizes,
but were important to include in the final analysis to increase comprehensiveness (and to
reduce selection bias), an effect size estimate of zero was entered. Assigning an effect
size of zero is a conservative procedure designed to prevent an inflated overall effect size
estimate, when including important, albeit incomplete information from particular studies
(Rosenthal, 1984). In the present study, an effect size of zero was entered only when the
data could not be converted to an effect size and the authors reported nonsignificant
differences between the active and placebo conditions. An effect size of zero was entered
for three of the pharmacological studies that reported nonsignificant differences between
the active versus the placebo conditions and the data in the articles were insufficient to
compute effect sizes.
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For between-subjects group designs, the traditional meta-analytic formula, first
proposed by Glass (1977), was utilized whereby unweighted effect sizes are calculated by
subtracting the control group mean from the treatment group mean, divided by the control
group (Glass, 1977) or the pooled standard deviation (standard deviation of treatment and
control or Cohen's

.d;Cohen, 1988). Because the size of the denominator (i.e., standard

deviation) in this formula can have a serious impact on the magnitude of effect, a
concerted effort was made to obtain the best estimate of the variance of an untreated
sample . Thus, in this study, the "pooled" standard deviation included the variance of the
treatment group before treatment in addition to the variance of the no-treatment or waitlist control group. This procedure is often helpful in obtaining a more accurate estimate
of the variance of an untreated group (Karl White, personal communication, February 19,
1998).
Despite the fact that a large number of meta-analytic reviews have used
unweighted effect size calculations (e.g., Casey & Berman, 1985; Smith et al., 1980),
there is a recent trend in the literature to use a weighted effect size procedure (e.g.,
DuPaul & Eckert , 1997; Weisz, Weiss, et al., 1995). The unweighted least squares model
(ULS) relies on several statistical assumptions, most notably the assumption of
homogeneity of variance. That is, the means and standard deviations (i.e., variance) are
equivalent across groups and observations. This assumption is closely related to
distribution and sample size factors. In meta-analytic studies, individual observations are
the ES. Thus, when aggregating a number of effect sizes (i.e., averaging effect sizes
across studies), the assumption of homogeneity of variance is often violated in meta-
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analytic reviews because many of the studies often have substantial differences in sample
sizes. The weighted least squares (WLS) general linear model has been described as a
more reliable way to compute effect size estimates since the procedure corrects for biased
estimates derived from smaller samples (Hedges & Olkin, 1985). In brief, this procedure
corrects for smaller samples by weighting the effect sizes by the inverse of its variance .
However , the WLS method has also met with criticism because comparisons
between previous ULS meta-analytic studies and more recent WLS studies are
problematic since it would be difficult to determine whether the differences were related
to the data or associated artifactually to the analytical procedures . In the meta-analysis
conducted by Weisz, Weiss, et al. (1995), they calculated effect size estimates using both
the ULS and WLS methods. Based on the six depression treatment studies included in
the analysis , the ULS effect size estimate was 0.67, whereas the WLS effect size estimate
was 0.64. Thus, practically speaking, the WLS method had little impact upon the average
effect size for depression treatment studies . In light of these data, coupled with the fact
that the DST AT program is based on the ULS model , the unweighted least squares model
was utilized in this study to facilitate comparisons across ULS meta-analyses .
For within-subjects group designs, unweighted effect sizes were calculated as
well. However , in these studies, the effect size was interpreted as the magnitude of
change observed in the experimental group from the pretreatment to posttreatment phases
(i.e., intrasubject variance) . It was hypothesized that these effect sizes would be larger in
general , due to the fact that the magnitude of these effect sizes were not mediated by the
measurement of change due to the mere passage of time (i.e., "treatment" effect for
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control group subjects) . As such, comparisons of within- and between-group effect sizes
were inappropriate. However , pre-/post-effect sizes were calculated for the betweengroup designs to facilitate a useful comparison of treatments across the two designs.
A variety of procedures were used to extract and subsequently analyze the data
from early-onset depression treatment studies. Comparisons of the main effects, potential
interactions , and other specified variables were conducted. Further, to gain an idea of the
robustness of the findings , two additional interpretive aids were used. In addition to
Cohen ' s (1988) guidelines, the magnitude of the overall mean difference effect sizes were
interpreted based on 95% confidence intervals (Cl) and a Fail Safe N procedure was used.
The Fail Safe N procedure , first used by Rosenthal (1979) and described by Cooper
( 1979), generally denotes the number of studies with null effects that would be needed to
reverse the conclusion that a statistically significant relationship exists based on the
criterion values , usually 12= .05 or .01 (Wolf, 1986). Orwin (1983) adapted this
procedure for meta-analytic designs whereby an effect size criterion value is substituted
for the probability values. Orwin suggested that Cohen's (1988) guidelines be used as the
criterion values (i.e., effect sizes between 0.20 and 0.49 = small; effect sizes between 0.50
and 0.79 = moderate ; effect sizes of 0.80 or greater= large). The Fail Safe N for metaanalytic designs is interpreted as the number of studies with a particular criterion value
(e.g., effect sizes = 0.20) that are required to bring down the average effect size to that
given criterion value (i.e., small effect). In essence, the Fail Safe N procedure helps to
account for one of the criticisms (i.e., selection bias) of meta-analyses in that it provides
an index of how many studies with "small" effects (unpublished or not included) that
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would be needed to diminish the overall effect size to a "small" effect.

Summary

In summary, a comprehensive sample of studies on the psychosocial and
pharmacological treatment of early-onset depression were located through an extensive
literature search. Articles that met the inclusionary criteria were subsequently analyzed.
The outcome data from 37 outcome studies were extracted and converted into effect
sizes. Comparisons of main effects, potential interactions, and other specified variables
were conducted . Finally, the data were discussed within the context of a number of
interpretive aids often used in meta-analytic designs.
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CHAPTER IV
RESULTS

The presentation ofresults is divided into the following four sections: (a)
descriptive statistics , (b) intercoder agreement ratings, (c) main effects, and (d) analysis of
study variables.

Descriptive Statistics

Psychosocial Studies
Of the 23 psychosocial studies included in the analysis, 14 (61%) were betweensubject group studies with wait-list , placebo , or no-treatment control groups. The
remaining nine (39%) psychosocial studies utilized a within-subject (pre/post) group
design . The psychosocial studies were published or conducted between 1980 and 1998,
with the vast majority of studies published after 1990 (i.e., 87%). There were 36 active
treatments across all 23 psychosocial studies and two attention-placebo conditions . The
modal treatment regimen was cognitive-behavioral group therapy (n = 11), followed by
nondirective , supportive individual therapy (n = 3), social skills group therapy (n = 3),
cognitive-behavioral individual therapy (n = 4), and relaxation group therapy (n = 2). The
remaining treatments included nondirective supportive group therapy, residential
treatment , behavioral group therapy, aerobic exercise, individual relaxation therapy, role
playing , family therapy, interpersonal therapy , and various combinations (e.g., group CBT
plus parent group or group CBT plus family therapy). There were three prevention

72
studies, 11 studies in which the subjects were targeted based on depressive
symptomatology, and nine studies where the subjects were included based on a
depressive diagnosis (i.e., major depressive disorder and/or dysthymic disorder).
In the between-subject group studies, there were 985 subjects between the ages of
7 and 18 years old. The number of subjects in each of the controlled studies ranged from
7 to 152 (median= 57.5). There were five (35%) controlled studies in which the average
age of the subjects was above 13 years old, whereas nine (65%) studies included subjects
with a mean age of below 13 years old. In the within-subject group designs, there were
391 subjects between the ages of 5 and 18 years old. The number of subjects in each of
the pre-/poststudies ranged from 8 to 107 (median = 46). Of the nine pre-/poststudies, six
(66%) included subjects with an average age above 13 years old, whereas three (33%)
studies included subjects with a mean age below 13 years old. The average percentage of
female subjects across all 23 studies was approximately 56%. However, only 3 of the 23
studies (13%) reported separate findings based on sex.
The number of therapy sessions in the controlled trials ranged from 8 to 27
(median= 10.5) and the number of weeks for each treatment ranged from 2 to 12 weeks
(median= 8). The number of sessions in the pre-/poststudies ranged from 5 to 36
(median = 11) and the number of weeks for each treatment ranged from 4 to 24 weeks
(median= 12). Of the 14 controlled studies, 9 (64%) included follow-up data, ranging
from 1 month to 1 year posttreatment (median= 6.5 weeks). Among the nine pre-/
posttrials, five (55%) included follow-up data, ranging from 1 month to 1 year
posttreatment (median= 4 months). See Table 1 for a descriptive summary.
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Table 1
Frequency and Percentage of Study Characteristics
Characteristics
Total number of studies reviewed
Number excluded
Reasons for exclusion
Single-subject or case report
Sample not at risk or depressed
No depression outcome measure
Insufficient data to compute ES
Total number of studies included
Type of study
Psychosocial treatment
Between-subject (controlled)
Within-subject (pre/post)
Pharmacological treatment
Between-subject (controlled)
Within-subject (pre/post)
Year of publication (psychosocial)
1980-1984
1985-1989
1990-1994
1995-1998
Year of publication (pharmacological)
1980-1984
1985-1989
1990-1994
1995-1998
Source of study
Published study
Dissertation or thesis
Unpublished manuscript
Follow-up assessment (psychosocial)
1-9 weeks
9-16 weeks
>16 weeks

Frequency

Percentage

55
18

100.0
32.7

8
3
2
37

44.5
16.7
11.1
27.7
67.3

23
14/23
9/23
14
14/14
0/14

62.2
60.9
39.1
37.8
100.0
0.0

1
2
8
12

4.3
8.7
34.8
52.2

3
2
6
3

21.4
14.3
42.9
21.4

34
2
1
14/23
5/14
1/14
8/14

91.9
5.4
27.7
60.8
35.7
7.1
57.2

5
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Pharmacological Studies
All 14 pharmacological studies included in the analysis were controlled clinical
trials with active medication and placebo conditions , with the exception of one study in
which an inactive placebo pill was combined with psychotherapy (Mandoki et al., 1997).
All 14 studies included subjects based on a diagnosis of major depressive disorder based
on DSM criteria (AP A, 1980, 1987, 1994) and information solicited from self-report
measures , interviews, and observations. The pharmacological trials were published or
conducted between 1981 and 1997 and 64% of studies were published after 1990. There
were 441 subjects between the ages of 6 and 19 years old. The number of subjects in each
of the pharmacological trials ranged from 6 to 96 (median= 30). There were six (43%)
studies in which the subjects were 12 years of age or younger, six (4 3% ) studies in which
the subjects were 13 years of age or older , and two (14%) studies in which there were
children and adolescents ranging from 7 to 17 years old (Emslie et al., 1997) and 8 to 17
years old (Mandoki et al., 1997). The average percentage of female subjects across all
pharmacological studies was approximately 42%. However , none of the studies reported
separate findings based on sex.
The types of medications used in the pharmacological trials included imipramine
(Tofranil; n = 4), amitriptyline (Elavil; n = 3), desipramine (Norpramin ; n = 2),
nortriptyline (Pamelor; n = 2), fluoxetine (Prozac; n = 2), and venlafaxine (Effexor;

n = 1). The number of weeks for each treatment ranged from 4 to 8 weeks (median= 6).
The outcome data in the pharmacological trials were reported at the end of the acute
phase of pharmacotherapy (i.e., posttreatment) . Follow-up data were not included in the
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original articles. See Table 1 for a descriptive summary.

lntercoder Agreement

As described in Chapter Ill, 25 psychosocial studies were double-coded by the
primary researcher and a second Ph.D. candidate in psychology. Although two of the
studies rated were not included in the final sample, the intercoder agreement data from
these studies were retained to increase the chances of obtaining valid reliability estimates
for the entire sample of studies. The pharmacological articles were not double-rated due
to the limited number of variables, relative to the psychosocial studies, that were deemed
suitable for coding. Two formulas were used to calculate the interrater agreement. First,
interrater agreement percentages were calculated by dividing the total number of CO by
the total number of observations TO and multiplied times 100. Second, Cohen's Kappa
(Cohen, 1960) was calculated for each variable to compensate for the limitations in the
first formula. Disagreements in the coding of any variables were reconciled through
consultation and clarification among the coders. Interrater agreement rates ranged from
88-100% with an average agreement of 95.3%. Kappa coefficients ranged from 0.76 to
1.00, with an average Kappa reliability coefficient of .91. See Table 2 for a summary of
intercoder agreement ratings on key study variables.

Main Effects

Psychosocial Studies
As mentioned previously, one of the primary objects of the current investigation
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Table 2
Intercoder Agreement and Cohen's Kappa of Study Variables
Study variable
Average age of subjects
Percent female
Referral source
Treatment setting
Type of treatment
Treatment variables
Frequency (sessions)
Length (weeks)
Assessment measures
Therapist variables
Severity of illness
Comorbidity
Quality of study

Intercoder agreement %

Cohen's Kappa

100
96
92
92
100

1.00
0.92
0.84
0.84
1.00

96
100
96
92
100
92
88

0.92
1.00
0.92
0.84
1.00
0.84
0.76

was to determine the overall efficacy of psychosocial interventions for child and
adolescent depression. Tables 3 through 6 provide a summary of key information
regarding study main effects. Based on a review of the 14 controlled psychosocial studies
(21 treatments) included in the analysis, the overall mean difference effect size at
posttreatment was 0.74 (range= 0.03 - 1.84; 95% CI 0.49 - 1.01), indicating that the
average child who received treatment for depression was better off than approximately
77% of the children who did not. Of the eight controlled psychosocial studies that
reported follow-up data, the mean effect size was 0.64 (range= 0.08 - 1.55; 95% CI 0.32
- 0.95), indicating that the average treated child was better off at follow-up (median= 6.5
weeks) than approximately 74% of control group subjects. Based on the Fail Safe N
formula with the criterion level set at 0.20 (i.e., small effect), it would take approximately
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Table 3
Overall Mean Effect Sizes at Posttreatment
Type of study

Mean ES

95%CI

Controlled psychosocial
14 (21 treatments)
.74
0.49 - 1.01
Intrasubject treatment
(1.23)
Intrasubject control
(0.37)
Pre-/postpsychosocial
9 ( 15 treatments)
0.75 - 1.52
1.14
Pharmacological
13
.19
-0.08 - 0.45
Note. Parenthetical ES values reflect amount of change on the dependent measures that
was observed in controlled studies using intrasubject (pre/post) variance estimates.

Table 4
Overall Mean Effect Sizes at Follow-up
Type of study
Controlled psychosocial
Pre-/postpsychosocial
Pharmacological

N

Mean ES

95% CI

8 ( 12 treatments)
5 (8 treatments)
13

.64
1.26

0.32 - 0.95
0.99 - 1.52

56 studies, all with effect sizes of 0.20, to bring down the overall posttreatment mean
effect size to 0.20
In regards to the nine pre-/postpsychosocial studies (15 treatments), the overall
mean effect size at posttreatment was 1.14 (range= 0.23 - 2.30; 95% CI 0.75 - 1.52). For
the five studies that reported follow-up data, the mean effect size at follow-up (median =
36 weeks) was 1.26 (range 0.95 - 1.94; 95% CI 0.99 - 1.52; see Tables 3 and 4). Based
on the Fail Safe N formula with the criterion level set at 0.20 (i.e., small effect), it would
take approximately 70 studies, all with effect sizes of 0.20, to bring down the overall
posttreatment mean effect size to 0.20.
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Table 5
Effect Sizes at Posttreatment and Follow-Up for Controlled Psychosocial Studies
Authors

Sample

Treatment

Post ES

.E-ES

Brown et al. ( 1992)

7 female adolescents
(ages 13-16) with
depressive symptoms

Aer Exer

0.18

Butler et al. (1980)

56 children
(ages 9-12) with
depressive symtoms

CBT-G
RP-G
Attn-Plac

0.09
0.29
-1.15"

Clarke et al. ( 1995)

120 adolescents
(ages 13-17) with
depressive symptoms

CBT-G

0.31

0. 10

Hickman (1994)

9 children (ages 8-11) with
depressive symptoms

SS-G

0.73

0.72

Jaycox et al. (1994);
Gillham et al. ( 1995)

143 "at-risk" children
(ages 10-13) with
depressive symptoms

CBT-G

0.31

0.31

Kahn et al. ( 1990)

68 children (ages 10-14)
with depressive symptoms

CBT-G
Rix-G
CBT-I

1.84
1.30
1.25

1.25
0.80
0.68

Lewinsohn et al. (1990)

59 adolescents (ages 14-18)
with MOD or Dysthymia

CBT-G
CBT-G + P

I.I I
1.45

Lewinsohn et al. ( 1996)

96 adolescents (ages 14-18)
with MDD or Dysthymia

CBT-G and
CBT-G+P

0.39

Liddle & Spence ( 1990)

31 children (ages 7-11)
with depressive symptoms

CBT-G
Attn-Plac

Rawson & Tabb (1993)

127 children (ages 8-12)
with depressive symptoms

Residential

0.40

Rei vich ( 1996)

152 "at-risk" children
(ages 12- 14) with
depressive symptoms

CBT-G
NST-G

0.03
0. 18

Reynolds & Coats
(1986)

30 adolescents (ages 14-18)
with depressive symptoms

CBT-G
Rix-G

1.48
1.57

Stark et al. (1987)

29 children (ages 9-12)
with depressive symptoms

CBT-G
BPS-G

0.93
0.68

Weisz et al. ( 1997)

48 children (ages 8-12)
with depressive symptoms

CBT-G

0.54

0.52
-0.51"

0.26
-0.33

0.20
0.08

1.27
1.55

0.51

Note . See Table 6 notes for abbreviations .
"Attention-Placebo group effect sizes not included in mean effect size calculations because they were not active
treatment conditions.
bFollow-up data reported but not suitable for conversion to effect sizes.

79

Table 6
Effect Sizes at Posttreatment and Follow-Up for Each Pre- and Postpsychosocial Study
Authors

Sample

Treatment

Post ES

F-ES

Brent et al. (1997)

107 adolescents
(ages 13-18) with MOD

CBT-1
SBFT
NST-1

2.30
1.61
2.04

Curry & Wells (1998)

I I adolescents
(ages 14-17) with MOD or
Dysthymia and comorbid
substance abuse

CBT-G + F

1.41

Fine et al. (1991)

66 adolescents
(ages 13-17)
with MDD or Dysthymia

SS-G
NST-G

0.23
0.76

King et al. ( 1990)

46 "at-risk " children
(ages 5-11)

SS-G
Consult

0.96
0.25

Mufson et al. (1994) ;
Mufson et al. (1996)

14 adolescents
(ages 13-16) with MOD

IPT-1

2 .02

1.94

Reed (1994)

8 male adolescents
(ages 14-19) with
MDD or Dysthmia

SS-G

1.45

0.95

Vostanis et al. ( 1996)

56 children and adolescent s
(ages 8-17) with
MDD or Dysthymia

CBT-I
NFI-1

1.30
0.89

1.28
0.95

Wagner et al. (1993)

30 female adolescents
(ages 9-15) with
depressive symptoms

NST-1

0.24

Wood et al. (1996)

53 children and adolescents
(ages 11-17) with
MDDorDD

CBT-1
Rix-I

1.33
0.30

1.12
1.16

1.43
1.27

Note . Aer Exer=Aerobic Exercise; Alt-Tx=Altemative Treatment; Attn-Plac=Attention-Placebo Group ;
CBT-G=Cognitive-Behavioral Therapy-Group; CBT-J=Cognitive-Behavioral Therapy-Individual ;
Consult=Consultation; F=Family Therapy; IPT-I=Interpersonal Psychotherapy-Individual; NFI-I=Nonfocused Intervention-Individual; NST-I=Non-Directive Supportive Therapy-Individual; P=Parent; PSG=Problem-Solving Group; PsyEd-G=Psychoeducational Group; Rlx-I=Individual Relaxation Therapy ;
Rlx-G=Group Relaxation Therapy ; RP-G=Role-Play Group; SS-G=Social Skills Group; SBFT=Structured
Behavior Family Therapy.
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However , because these effect sizes were calculated based on intrasubject
variance , the mean effect size reflects an overall decrease in the amount of depressive
sequelae as measured by the various outcome instruments across all studies. Without
control group comparisons , it was virtually impossible to estimate how much of the
treatment effect, as determined by the dependent measures , was attributable to the
treatment as opposed to extraneous factors such as the mere passage of time . Therefore ,
in order to facilitate a useful comparison of the mean effect sizes of the between- and
within-subject group designs, pre-/post-effect sizes were also calculated for the controlled
studies. The overall mean effect size for controlled studies using intrasubject variance
estimates was 1.23 (range= 0.30 - 2.27; 95% CI .90 - 1.55), which was comparable with
the average effect size for the pre-/poststudies (i.e., ES = 1.14). To gather an
understanding of the amount of change that occurred without treatment , pre-/post-effect
sizes were calculated for control group subjects only. The pre-/post-effect size
calculations for control group subjects yielded a mean effect size of 0.3 7 averaged across
the 14 studies . These data approximate the amount of change between the pretreatment
and posttreatment phases that could not be explained by or attributed to the therapeutic
interventions themselves (see Table 3).

Pharmacological Studies
Of the 14 pharmacological trials that compared active versus placebo response
rates, effect sizes were entered for all but one study (i.e., Mandoki et al., 1997), due to the
fact that the active medication was compared to a placebo plus psychotherapy condition,
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thus introducing a confound to the comparison. Moreover, the authors reported that
almost 66% of the subjects in both conditions responded positively to the treatment.
Nonetheless, the overall mean effect size of the pharmacological studies at posttreatment
was 0.19 (range -0.88 - 1.19; 95% CI -0.08 - 0.45), suggesting that the average subject
who was administered the active medication moved to the 58th percentile in the
distribution of subjects who took the placebo. Follow-up data were not reported in the
pharmacological studies (see Tables 3, 4, and 7). Because the magnitude of the mean
effect size for pharmacological studies was below Cohen's suggested guidelines for a
"small effect," the Fail Safe N formula was not calculated.

Analysis of Study Variables

As previously noted, no published studies were located that addressed specifically,
the potential interaction between age and the treatment of early-onset depression . To
complicate matters, differentiating between "child" and "adolescent" samples can be
erroneous and potentially misleading. However, in order to facilitate a useful analysis of
the potential interaction of age and treatment outcome, a false dichotomy was created
whereby child studies were defined as having a mean age of 12 or younger and adolescent
studies were characterized by a sample with a mean age of 13 or older. Although the
most appropriate differentiation between child and adolescent samples remains the
subject of much debate, the aforementioned definitions appear most frequently in the
published literature (e.g., Emslie et al., 1997; Weisz, Weiss, et al., 1995). Further, the
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Table 7
Effect Sizes Comparing Active Versus Placeboy Positive Response Rates for Controlled
Pharmacological Studies
Authors

Sample

Treatment

ES

Boulos et al. ( 1991)

30 adolescents (ages 15-19)
with MDD

Desipramine

0.44

Emslie et al. (1997)

96 children and adolescents
(ages 7-17) with MDD

Fluoxetine

0.59

Geller et al. (1990)

31 adolescents (ages 12-17)
with MDD

Nortriptylin e
SMDES-CDRS

-0.61
(0.49)

Geller et al. ( 1992)

50 children (ages 6-12)
with MDD

N ortripty line
SMDES-CDRS

0.46
(1.12)

Hughes et al. ( 1990)

27 children (ages 6-12)
with MDD and Comorbid
Anxiety or CD/ODD

Kashani et al. (1984)

9 children (ages 9-12)
with MDD

Am itripty Iine

20 adolescents (ages 13-17)
with MDD

Amitriptyline

60 adolescents (ages 15-19)
with MDD

Desipramine

Kramer & Feiguine (1981)
Kutcher et al. (1994)
Kye et al. ( 1996)
Mandoki et al. ( 1997)
Petti & Law (1982)
Preskom et al. (1987)

Puig-Antich et al. (1987)
Simeon et al. (1990)

22 adolescents (ages 12-17)
with MDD

Imipramine
MDD+Anx
MDD+
CDD/ODD

0.34
1.19

Amitriptyline
SMDES-HAM-D
Venlafaxine

6 children (ages 6-12)
with MDD

Imipramine

38 children (ages 6-12)
with MDD

o.oo·
o.oo·

33 children and adolescents
(ages 8-17) with MDD

22 children (ages 6-12)
with MDD

0.07
(1.02)
(-0.88)

(0.53)

0.12

Imipramine
% change CDRS
% change CD!

0.14
(0.21)
(0.06)
-0.31

Imipramine

o.oo·

30 adolescents (ages 13-18)
Fluoxetine

Note. Anx=Anxiety; CDE=Children's Depression Inventory; CDRS=Child Depression Rating Scale;
HAM-D=Hamilton Rating Scale for Depression; MDD=Major Depressive Disorder; ODD=Oppositional
Defiant Disorder; SMDES=Standard Mean Difference Effect Size.
•zero entered due to insufficient data to compute ES estimates and nonsignificant differences reported for
active versus placeboy comparisons. Parenthetical ES values reflect separate calculations based on data
from dependent measures contained in the articles or outcomes based on interactional variables .
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age-by-treatment outcome interactions were discussed within the context of each type of
study. That is, separate findings were reported for controlled psychosocial, pre-/
postpsychosocial, and pharmacological studies.
In the nine controlled psychosocial studies where the average age of the subjects
was 12 or younger, the mean effect size was 0.65 (95% CI 0.34 - 0.95). In contrast, the
five controlled adolescent studies yielded an average effect size of 0.93 (95% CI 0.36 1.49). In regards to pre-/postpsychosocial studies, the mean effect size for child samples
was 0.73 (95% CI 0.14 - 1.30), whereas the mean effect size for the six adolescent studies
was 1.35 (95% CI 0.83 - 1.85).
Regarding to the pharmacological trials, there were six studies in which the
average age was 12 or younger, seven studies in which the average age was 13 or older,
and one study in which the ages ranged from 7 to 17 years (Emslie et al., 1997).
However, the authors stratified the sample by age (:S 12 and 2::13) and reported no
differences in outcome based on age. Therefore, age-by-treatment outcome data from this
study were included in the child and adolescent analyses. For child pharmacotherapy
trials, the mean effect size was 0.15 (95% CI -0.12 - 0.42), whereas adolescent
pharmacological studies yielded an average effect size of 0.28 (95% CI -0.24 - 0.79). See
Table 8 for a summary of data on age and mean effect size.

As described above, the interaction between sex and therapy outcome has been
investigated. However, despite some interesting trends, the relationship between sex and
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Table 8
Mean Effect Sizes Based on Average Age of Sample
Type of dtudy

Mean ES

95%CI

Controlled psychosocial
0.65
Child studies
9
0.34 - 0.95
Adolescent studies
0.93
0.36 - 1.49
5
Pre-/postpsychosocial
0.73
0.14 - 1.30
Child studies
3
Adolescent studies
1.35
0.83 - 1.85
6
Pharmacological
Child studies
7
0.15
-0.12 - 0.42
Adolescent studies
(8)
0.28
-0.24 - 0.79
Note. Parenthetical N refers to the data from the Emslie at al. ( 1997) study which was
included in both classifications.

outcome is unclear, especially in relation to the treatment of early-onset depression.
Nonetheless, given the epidemiological data which indicate that the female-to-male ratios
for depressive illness begin to approximate the base rates for adult depressive disorders
(i.e., approximately 2: 1) during middle to late adolescence, it would be important to know
whether there are trends of differential efficacy based on sex.
Exploratory correlational analyses revealed little in terms of an interaction
between sex and psychosocial depression treatment outcome. For example, the Pearson
product-moment correlation between the percentage of female subjects and the mean
effect size in controlled studies was 0.16

fu = .48) and explained approximately

2.5% of

the variance. Furthermore, the correlational data from pharmacological trials were even
more dismal, which could be attributed, in part, to the truncated range of female
percentages observed across medication studies.
However, when the data from psychosocial studies were analyzed by calculating
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effect sizes using different percentages of female subjects as criteria, there were some
noteworthy findings. For example, when the percentage of female subjects in controlled
studies was 60 or greater (i.e., the majority), the mean effect size was 0.90, as compared
to an effect size of 0.63 when the percentage of female subjects was below 60. Similarly,
in pre-/poststudies, when the percentage of female subjects was 60 or greater, the average
effect size was 1.20, whereas the mean effect size was 1.04 when the percentage of
female subjects dropped below 60 . See Table 9 for a summary of data on sex and effect
size.

Referral Source
As mentioned previously, the interaction between referral source and treatment
efficacy has important implications for clinicians and researchers. Based on the 36
psychosocial treatment regimens (23 studies) included in this review, there were 15
clinically referred and 21 nonreferred groups . Most of the clinically referred samples
occurred in the context of within-subject designs (i.e., 12), whereas there was a
predominance of nonreferred samples in the controlled trials (i.e., 18). In regard to
pharmacological interventions, all of the samples were clinically referred children with a
diagnosis of major depressive disorder. Thus, the interaction between referral source and
pharmacotherapy was not examined .
The mean effect size for clinically referred subjects in controlled trials was 0.44,
whereas the average effect size for nonreferred youngsters in controlled trials was 0.79.
Comparatively, the mean effect size was 1.20 for clinically referred children in pre-/
poststudies. In the case of nonreferred children and adolescents in within-subject designs,
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Table 9
Interaction Between Effect and Sex in Psychosocial Studies
Type of study
Controlled studies
::: 60% female
< 60% female
Pre-/poststudies
::: 60% female
< 60% female

N

Mean ES

8

0.90
0.63

6
5

4

1.20
1.04

the average effect size was 0.89. See Table 10 for a summary of findings .

Treatment Setting
In the present investigation , 36 psychosocial treatments were delivered in school
settings , outpatient clinics, and inpatient hospitals . The school (n = 15; 71% ) was the
modal setting in controlled psychosocial trials, whereas the outpatient clinic (n = 12;
80%) was the predominant setting in pre-/poststudies . In terms of pharmacological
studies , there were six inpatient trials, seven outpatient trials, and one study in which the
treatment setting could not be accurately determined but included a number of outpatients
(i.e., Simeon et al., 1990).
The average effect size for controlled studies conducted in schools was 0.75.
Controlled psychosocial treatments conducted in outpatient settings (n = 4) yielded a
mean ES of 0.92. In terms of the pre-/poststudies , outpatient treatments produced an
average ES of 1.22, whereas the two school-based interventions yielded a mean ES of
0.61. Medication trials conducted in outpatient settings (effect sizes = 0.26) produced a
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Table 10
Interaction Between Effect Size and Referral Source in Psychosocial Studies
Type of study
Controlled studies
Referred
N onreferred
Pre-/poststudies
Referred
N onreferred

N (treatments)

Mean ES

95%CI

3
18

0.44
0.79

-0.25 - 1.12
0.50 - 1.08

12
3

1.20
0.89

0.74 - 1.66
-0.61 - 2.38

higher mean effect size than inpatient regimens (effect sizes= -0.06). See Table 11 for a
summary of data on treatment setting and effect sizes.

Type of Treatment
As reported above, one of the major objectives of this investigation was to
examine the differential effectiveness of a variety of treatment modalities in ameliorating
depressive sequelae in children and adolescents. As presented in Table 12, the modal
psychosocial intervention for depressed youth was cognitive-behavioral group therapy
(n = 11; 31%), which yielded an average effect size of0.69. Other common interventions

included nondirective supportive individual therapy (n = 3; 8%; Mean effect size= 1.05),
cognitive-behavioral individual therapy (n = 3; 8%; Mean effect size= 1.64), social skills
group therapy (n = 3; 8%; Mean effect size= 0.88), and relaxation group therapy (n = 2;
6%; Mean effect size= 1.43). Further, there were two attention-placebo conditions that
yielded an average effect size of -0.83. See Tables 12 and 13 for a summary of data on
treatment type and effect size.
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Table 11
Mean Effect (ES) Based on Treatment Setting
Type of study
Controlled psychosocial
School
Outpatient
Inpatient
Pre-/pospsychosocial
School
Outpatient
Pharmacological
Outpatient
Inpatient

N (treatments)

Mean ES

95%CI

15
4
2

0.75
0.92
0.29

0.42 - 1.08
0.18 - 1.62
-1.10-1.68

2
13

0.61
1.22

-3.90 - 5.11
0.80 - 1.64

8
6

0.26
-0.06

-0.20 - 0.73
-0.13 - 0.12

Table 12
Mean Effect Size by Treatment Modality in Controlled Psychosocial Studies
Treatment

N (treatments)

Aerobic exercise
Attention placebo
Behavioral Problem-solving
CBT group
CBT group+ family
CBT-individual
Nondirective support group
Residential
Relaxation group
Role play
Social skills group
Note. CBT=Cognitive-Behavioral Therapy.

1
2
1
11
1
1
1
1
2
1
1

Mean ES
0.18
-0.83
0.68
0.69
1.45
1.25
0.18
0.40
1.43
0.29
0.73
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Table 13
Mean Effect Size by Treatment Modality in Pre- and Poststudies
Treatment
CBT group+ family
CBT-individual
SB family therapy
Individual consultation
Interpersonal therapy-ind
Nondirective individual
Relaxation-individual
Role play
Social skills group

N (treatments)

Mean ES

1
3
1
1
1
3
1
1
3

1.41
1.64
1.61
0.25
2.02
1.05
0.30
0.29
0.88

Note. CBT=Cognitive-Behavioral Therapy; Ind=Individual; SB Family
Therapy=Structured Behavioral Family Therapy.

In regards to the types of medications used in the pharmacological trials, the TCA
imipramine was used most often (n = 4; 29%) and yielded an average effect size of 0.02.
Other TCAs administered in medication trials included amitriptyline (n = 3; 21 %; Mean
effect size= 0.40), desipramine (n = 2; 21 %; Mean effect size= 0.39), and nortriptyline
(n = 2; 21 %; Mean effect size = -0.15). The SSRI fluoxetine was used twice and

produced an average effect size of 0.30. See Table 14 for a summary of medication type
and effect size.

Other Treatment Variables
Although there is a need to better understand the relationship between the length
and frequency of treatment and the efficacy of child and adolescent depression
interventions, exploratory analyses did not yield many compelling trends. For example,
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Table 14
Mean Effect Size by Medication in Pharmacological Studies
Medication
Amitriptyline (Elavil)
Desipramine (Norpramin)
Fluoxetine (Prozac)
Imipramine (Tofranil)
Nortriptyline (Pamelor)

N (treatments)

Mean ES

3
2
2
4
2

0.40
0.39
0.30
0.02
-0.15

the Pearson product-moment correlation between the standard mean difference effect size
and the number of therapy sessions was -0.03 (Q = .86). However , there was a modest
negative relationship between the number of weeks in therapy and the mean effect size
(r = -0.40; 12.= .07). That is, as the number of treatment weeks increased, the average

effect size decreased . Moreover , in terms of the pharmacological interventions , the
problem of truncated range (i.e., 4-8 weeks) precluded a meaningful analysis between the
duration of treatment and outcome.

Assessment Measures
As described previously, the process of assessment has a significant impact on
treatment outcome studies because the assessment and diagnostic measures that guide the
inclusion and evaluation of subjects are used to determine the effectiveness of the
interventions. Of the 23 psychosocial studies , a single self-report measure was used to
evaluate the treatment in 8 (35%) of them. Further , two other investigations used a
combination of two self-report measures to assess outcome. The most commonly used
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the studies, the adult version of the CDI, the BDI, was administered to the adolescent
subjects. Other commonly used self-report measures included the RCDS, the RADS , the
MFQ , and the CES-D .
In terms of combining assessment procedures, 9 of the 23 studies (39%) used both
self-report measures and diagnostic interview schedules . The modal interview schedule
used was the K-SADS (n = 7) followed by the CDRS (n = 3) and BID (n = 3). Measures
of anxiety (e.g., Revised Children's Manifest Anxiety Scale; Reynolds & Richmond,
1978) were used in three of the studies and the CBCL was used in two trials . There was
also the sporadic use of other instruments that purport to measure constructs such as selfesteem, global functioning, and cognitive distortions (Butler et al., 1980).
Although the interaction between assessment technology and outcome was
identified as an important issue to examine, it proved difficult to analyze logistically.
However , in a number of studies, depression outcome measures were used in concert .
Thus , practical comparisons of two different measures within the same study revealed
some interesting findings . As shown in Table 15, the assessment strategy often had a
noteworthy impact on the ES estimates . For example , Kahn et al. (1990) used the RADS
and the CDI in their study to evaluate the efficacy of cognitive-behavioral group therapy.
The mean effect size based on the CDI was 1.52, whereas the mean effect size based on
the RADS was higher at 2.17. In another study, Reynolds et al. (1986) used the BDI and
the RADS to assess the effectiveness of cognitive-behavioral group therapy. Based on
the data, the findings were much more convergent, with the mean effect size on the BDI
at 1.50 and a mean effect size of 1.46 on the RADS .
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Table 15
Within-Study Effect Size Comparisons of Assessment Measures
Study

Treatment

Measure

ES

Clarke et al. (1995)

CBT-G

CES-D
HRSD

0.31
0.28

Jaycox et al. (1994)

CBT-G

CDI
RCDS

0.27
0.35

Kahn et al. (1990)

CBT-G

CDI
RADS

1.52
2.17

Rlx-G

CDI
RADS

1.09
1.50

CBT-I

CDI
RADS

1.04
1.47

CBT-G

CES-D
BDI

1.26
0.96

CBT-G + F

CES-D
BDI

1.60
1.29

Reynolds et al. ( 1986)

Rlx-G

BDI
RADS

1.58
1.56

Preskom et al. (1987)

Imiprarnine

CDI
CDRS

0.21
0.06

Lewinsohn et al. (1990)

CDI
0.47
CDRS-R
0.38
Note. BDI=Beck Depression Inventory ; CBT-G(I)=Cognitive-Behavioral Therapy-Group
(Individual; F=Farnily); CDI=Children's Depression Inventory; CDRS Children's
Depression Rating Scale (R=Revised); CES-D=Center for Epidemiological Studies-Depression Scale; HRSD=Harnilton Rating Scale for Depression; RADS=Reynolds
Adolescent Depression Scale; RCDS=Reynolds Child Depression Scale; RixG=Relaxation Group.
Weisz et al. ( 1997)

CBT-G
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Therapist Variables
As previously described, therapist variables such as level of training, years of
experience, and professional discipline are important to consider when evaluating therapy
outcome. However, due to limited information contained in the articles, only the
therapist's level of training for psychosocial interventions was coded that included (a)
paraprofessional therapists (e.g., teachers), (b) graduate trainees, and (c) professional
therapists.
Of the 21 controlled psychosocial treatments, graduate students were most often
in charge of the therapeutic interventions (n = 15; 71% ) and produced a mean effect size
of 0.69. Professional therapists led four of the controlled treatments (19%), yielding an
average effect size of 1.18. There were only two controlled studies in which
paraprofessional therapists led the treatment , producing a mean effect size of 0.29.
In terms of the 15 pre-/posttreatments, professional therapists led 11 of them
(73%) and produced a mean effect size of 1.29. In the remaining four pre-/
posttreatments (27%), graduate students and paraprofessional therapists yielded mean
effect sizes of 0.85 and 0.61, respectively . See Table 16 for a summary of data on
therapist variables and effect size.

Severity of Illness and Comorbidity
As mentioned above, it is important to know whether treatment efficacy is
affected by the severity of the depressive illness. Thus, three levels of severity were
coded and analyzed including: (a) "at risk" status (i.e., prevention), (b) presenting
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Table 16
Mean Effect Size by Level of Training in Psychosocial Studies
Type of study

Training level

N

Mean ES

Professional
Graduate student
Paraprofessional

4
15
2

1.18
0.69
0.29

Professional
Graduate student
Paraprofessional

11
2
2

1.29
0.85
0.69

Controlled psychosocial

Pre-/postpsychosocial

depressive symptomatology, and (c) depressive diagnosis (major depressive disorder).
While there were different levels of severity in the psychosocial studies, the
pharmacological studies uniformly assessed the subjects as suffering from major
depressive disorder.
Of the 21 controlled psychosocial treatments, three were determined to be
prevention regimens with a mean effect size of0.17. There were 15 treatments based on
depressive symptomatology that yielded an average effect size of 0.81, whereas the
remaining 3 treatments purported to address a diagnosis of major depressive disorder and
produced a mean effect size of 0.98.
In terms of the 15 pre-/postpsychosocial interventions, 12 of the treatments
focused on depressive diagnoses, 2 were designed to address at-risk status, and 1
intervention targeted depressive symptomatology. The pre-/posttreatments for major
depressive disorder produced a mean effect size of 1.32, the prevention treatments yielded
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an average effect size of .49, and the single symptomatology-based intervention yielded
an average effect size of 0.24. Refer to Table 17 for a summary of data on level of
severity and effect size .
Unfortunately, the data regarding comorbidity in the studies were limited and did
not facilitate many useful analyses. Although descriptive data regarding comorbid
conditions were provided in a few studies, the data were not suitable for coding to
investigate potential interactions. Further, in the single psychosocial study that
specifically addressed comorbid conditions (i.e., Curry & Wells , 1998; depression and
substance abuse), substance abuse data were not available at the time of this writing.
However , one finding is important to note. In a pharmacological trial in which the
efficacy of imipramine was examined (Hughes et al., 1990), the authors reported an
interaction between major depressive disorder , comorbid conditions , and outcome .
Patients with major depressive disorder and comorbid anxiety disorders responded much
better to the medication (Mean effect size = 1.02) than those with major depressive
disorder and comorbid conduct disorder and/or oppositional defiant disorder (Mean effect
size= -0.88). Thus, while there appeared to be null main effects, when the interaction
between comorbid conditions was taken into account , the data were much more practical
and useful.

Quality of Study
As described above , several researchers have suggested that there is a relationship
between methodological factors (i.e., study quality) and effect size estimates . The quality
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Table 17
Mean Effect Size by Level of Severity in Psychosocial Studies
Type of study

Level of severity

N (treatments)

Mean ES

Controlled psychosocial
Prevention
Symptomatology
Diagnosis

3
15
3

0.17
0.81
0.98

Prevention
Symptomatology
Diagnosis

2
1
12

0.49
0.24
1.32

Pre-/postpsychosicial

of each study was rated based on: (a) potential threats to internal validity and (b) the
overall validity of the study. Evaluative guidelines for study quality were based on a
5·-point Likert scale (1 = unacceptable, 2 = inferior, 3 = fair, 4 = good,; 5 = excellent).
The standard mean difference effect size estimates were cross-tabulated with the overall
validity ratings for each study. Based on a linear regression model, the correlation
between study quality and effect size was 0.67 CJ2< .0001). That is, as the study quality
increased, so did the standard mean difference effect size. See Figure 2 for a graphic
representation of these data.
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Figure 2. Relationship between study quality and standard mean difference effect sizes.

98
CHAPTER V
DISCUSSION

The three research questions that were posed in this investigation addressed : (a)
the overall efficacy of psychosocial interventions for child and adolescent depression, (b)
the overall efficacy of pharmacological treatments for child and adolescent depression,
and (c) whether there was evidence of differential efficacy for psychosocial and
pharmacological treatments when a number of variables were considered . This chapter
includes a detailed interpretation of the results followed by a review of the clinical
implications of the findings. The limitations of this investigation are discussed and
suggestions for future research are presented.

Main Effects

Psychosocial Studies
The results of this comprehensive review indicate that overall, psychosocial
treatments for early-onset depression lead to a substantial reduction in depressive
sequelae in children and adolescents regardless of whether the experimental design was a
between- or within-group study. The overall mean difference effect size for controlled
studies was 0.74 at posttreatment, indicating that the average child who received
treatment for depression was better off than approximately 77% of the children who did
not. Furthermore, the treatment effects were durable over a brief period of time
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(median= 6.5 weeks), as the mean effect size was 0.64 for the controlled studies that
reported follow-up data.
A practical interpretation of the overall effect sizes for controlled studies suggests
that the effects were robust and clinically meaningful. That is, a mean change of 0.74
standard deviation units across a variety of instruments that purport to measure depressive
sequelae would move a number of youth in the treated group from a clinical range to a
nonclinical range. For example, Stark et al. (1987) reported that the mean CDI score of
the treated group was 8.04 at posttreatment , as compared to 18.60 for the control group .
Thus , with a standard deviation of approximately 10 on the CDI, an effect size of0 .74
would account for almost an 8-point difference on the CDI scores at posttreatment. This
difference , in turn, moved a large group of treated subjects into the nonclinical range (i.e.,
< 11) based on the suggested interpretation of CDI scores by the instrument's author
(Kovacs , 1992).
These findings mirror global reviews of psychotherapy with children whereby the
treated youngsters fared much better than wait-list or no-treatment control subjects at
posttreatment and follow-up (effect size= 0.71; Casey & Berman , 1985; effect size=
0.88; Kazdin et al., 1990; effect size= 0.79 ; Weisz et al., 1987; effect size= 0.71 ; Weisz ,
Weiss, et al., 1995). These data are also convergent with the findings from more
circumscribed meta-analytic reviews that support the efficacy of social skills
interventions for depressed youth (effect size= 0.76; Black-Cecchini, 1996), cognitivebehavioral therapy for adolescents (effect size = 1.02; Reinecke et al., 1998), and a
smaller sample of depression treatments (effect size= 0.67; Weisz, Weiss et al., 1995).
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Furthermore, these findings are consistent with the data from a large number of studies
that support the efficacy of psychosocial treatments for depressed adults.
In regards to the pre-/postpsychosocial studies, the overall mean effect size at
posttreatment was 1.14, which indicates that the treated subjects experienced significant
reductions in depression at posttreatment. These findings were also durable over time
(median= 36 weeks), with a mean effect size of 1.26 for the studies in which follow-up
data were reported . However, as mentioned previously, these effect sizes were
calculated based on intrasubject variance and comparisons between the overall effect size
of the controlled and pre-/poststudies were inappropriate. Therefore, in order to facilitate
a useful comparison of the mean effect size of the between- and within-subject group
designs, pre-/post effect sizes were also calculated for the controlled studies. The overall
mean ES for controlled studies using intrasubject variance estimates was 1.23, which is
comparable to the mean effect size for pre-/poststudies (1.14).
Given these roughly commensurate values, a case could be made that the
treatments in pre-/poststudies led to equally substantial reductions in depressive sequelae
despite the methodological limitation of not having wait-list or no-treatment control
group comparisons. Further, if the data regarding the average reduction of depression in
control-group subjects (0.37) is subtracted from the pre-/post-effect size estimates of
treated subjects in between-group studies (1.23), the resulting value (0.86) approximates
the overall mean effect size for controlled studies (0.74). Therefore, although the overall
effect size for pre-/poststudies was relatively inflated because there were no wait-list or
control group comparisons, the similar pre-/postvalues across methodological designs
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augment the overall findings that psychosocial interventions are efficacious in the
treatment of early-onset depression.

Pharmacological Studies
The results of this meta-analytic review indicate that in general, pharmacological
treatments for early-onset depression do not lead to a substantial reduction in depressive
sequelae in children and adolescents. The overall mean effect size at posttreatment was
0.19, suggesting that the average subject who was administered the active medication
moved to the 58th percentile in the distribution of subjects who took a pharmacologically
inert placebo. It is unclear whether these effects were maintained over time as follow-up
data were not reported in the pharmacological studies. Further, the average placebo
response rate across all of the studies was high (43%; range 17% - 68%), indicating that
much of the derived benefits from pharmacotherapy were produced by the children's
expectations of the treatment as opposed to the active medication itself.
In comparison to the only other meta-analytic review located on the efficacy
pharmacotherapy for depressed youth (ES= 0.35; Hazell et al., 1995), these findings were
somewhat more discouraging but roughly consistent, suggesting that antidepressant
medications are not substantially superior to placebo in treating depressed youth. At the
same time, these data are inconsistent with the empirical evidence that the use of
psychotropic medications in adults suffering from depression is efficacious, with an
average positive response rate between 65% and 75% (Elkin, 1994; Speier et al., 1995;
Thase & Kupfer, 1996).
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However, a number of important points must be made about the interpretation of
these main effects . First, as Conners (1992) aptly pointed out, "various methodological
problems limit the conclusions" of pharmacological studies since there are substantial
differences in the criteria for improvement , instrumentation , and selection procedures.
Thus, in the present investigation, the pharmacological findings represent a synthesis of
data that are, in many ways, flawed (i.e., difficulty transforming response rates to effect
sizes) . For example, in one study improvement might be defined as evidencing a 50%
reduction in depressive symptoms as measured by the CDI, whereas one of the criteria for
improvement in another study might be a score of 26 or less on the CDRS. The resulting
dichotomous determinations of "improved " versus "not improved" in the active and
placebo conditions are markedly different across the two studies, which , in turn , renders
the calculation and comparison of effect sizes across the divergent improvement criteria
problematic. Nonetheless , these data certainly reveal some important trends about the
efficacy of pharmacological treatments for depressed youngsters and the findings are
congruent with most , if not all, of the qualitative interpretations presented within each of
the studies .
Second , as a number ofresearchers have suggested (Anderson , 1995; Birmaher et
al., 1996a; Kye & Ryan, 1995), firm conclusions about the efficacy of antidepressants in
young people cannot be made until a larger body of literature is accumulated whereby
some of the methodological limitations are addressed in future studies. Furthermore, of
the 14 pharmacological studies included in the present analysis , only two controlled trials
(14%) were located that utilized an SSRI (Emslie et al., 1997; Simeon et al., 1990). The
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vast majority of the trials (n = 11) used TCAs (79%). Thus, the negative main effects of
antidepressant medications for early-onset depression are attributable primarily to a lack
of TCA efficacy, not necessarily pharmacotherapy overall.
Third, the number of weeks of pharmacotherapy across studies ranged from 4 to 8
weeks (median= 6). Thus, given the fact that it often takes a month or more to evidence
benefits from TCAs (Duman et al., 1997), it is possible that posttreatment evaluations
were premature and not enough time had passed to accurately assess the effects of the
medications.
Given the limited evidence of TCA efficacy in children and the curiously high
placebo-response rates in younger groups, several researchers have attempted to explain
these findings based on the principles of pharmacokinetics. According to Stedman's
Medical.l)ictionarv (1995), pharmacokinetics is defined as "the process by which a drug
is absorbed, distributed, metabolized and eliminated by the body" (p. 630). For example,
Geller et al. suggested that more frequent dosing is required for children and adolescents
in light of the fact that they metabolize and excrete many of the antidepressant
compounds more rapidly than adults (Geller et al., 1986). Similarly, several authors have
reported statistically significant correlations between higher plasma levels of TCAs and
clinical improvement in children with major depression (e.g., Preskom et al., 1982; PuigAntich et al., 1987). However, this finding is equivocal and in need of replication
(Birmaher et al., 1996a). For instance, Clein and Riddle (1995) reported that

the lack of demonstrated efficacy of TCAs in double-blind, placebocontrolled studies in the treatment of childhood depression does not appear
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to be a pharmacokinetic phenomenon because frequent dosing has
adequately addressed this issue. (p. 68)
Other pharmacokinetic hypotheses have been proposed to explain the lack of
antidepressant efficacy in children and adolescents. Murrin, Gibbens, and Ferrer (1985)
suggested that because most of the antidepressant medications (i.e., tertiary amines ,
noradrenergic TCAs) that were used in the trials purportedly enhance noradrenergic
functioning , the fact that the noradrenergic systems are not fully developed until
adulthood might dampen or limit the effectiveness of such medications in children . In
contrast , there is evidence that the serotonergic and cholinergic systems develop earlier
(Clein & Riddle, 1995), which might set the stage for additional controlled studies of the
SSRis in children and adolescents in the future. It has also been suggested that the lack of
positive response to antidepressant medications in adolescents might be due to hormonal
factors that interfere with certain TCAs during puberty (Birmaher et al., 1996a).
In terms of the high placebo response rates in child and adolescent samples , a
number of hypotheses have been advanced. For example , Morris and Beck (1974)
suggested that children have generally higher placebo response rates than adults. In
addition , Birmaher et al. noted a number of potential factors associated with the high
placebo response rates including: (a) the instability of affective states in juvenile groups ;
(b) the inclusion of children who evidence only mild to moderate depressive
symptomatology; and (c) the prevalence of comorbid syndromes, especially disruptive
behavioral disorders (Birmaher et al., 1996a).
A third and final comment about the interpretation of the main effects of
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pharmacological trials is based on the interaction between study variables (e.g., length of
treatment, age , treatment setting, medication type) and outcome . Indeed, a number of
interesting trends were revealed about the efficacy of pharmacological interventions when
several variables were taken into account. These data are summarized in the following
section on Study Variables.

Summary
In summary, it appears that psychosocial interventions lead to substantial
reductions of depression in youngsters, whereas pharmacological interventions are not
superior to pill placebo in ameliorating depressive sequelae in children . There was only
one study (Mandoki et al., 1997) in which pharmacotherapy was compared with an active
psychosocial treatment and both interventions led to substantial reductions in depression
as determined by the outcome measures . Nonetheless, because the evidence is somewhat
indirect, it appears that psychosocial interventions are superior to pharmacotherapy in
treating depression in youth given the current findings reported in the literature . At the
same time, the methodological limitations of the pharmacological studies are noteworthy
and may be masking otherwise efficacious findings. Further, in light of the interactions
between study variables and outcomes that are discussed in the following section ,
comparisons between psychosocial and pharmacological interventions are placed within a
more appropriate context.
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Study Variables

As described previously, a false dichotomy was created whereby child studies
were defined as having a mean age of 12 or younger and adolescent studies were
characterized by a sample with a mean age of 13 or older. In the psychosocial studies, the
mean effect size for adolescent samples were higher than the mean effect size for child
samples, regardless of experimental design. These findings were consistent with a prior
study in which the mean effect size was higher for adolescents than for younger children
(Weisz, Weiss, et al., 1995). However, these data were divergent from an earlier study in
which psychotherapy was more efficacious for children than for adolescents (Weisz et al.,
1987).
Similarly, the interaction between age and pharmacotherapy indicated that
medication was more effective for adolescents than for children. Indeed, the mean ES
was almost twice as large for adolescents (0.28) as it was for children (0.15) . Thus,
overall , it appears that psychosocial and pharmacological interventions for depressed
youth are more effective for adolescents than for children. Although the reasons for
these moderate findings of differential effectiveness based on age are difficult to
determine, some possible hypotheses are offered. Based on the descriptive data, the
modal psychosocial treatment was cognitive-behavioral therapy in group, individual, or
family formats. Further, given the fact that a number of CBT interventions might depend
upon a certain level of cognitive development, younger children might not be as
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responsive to more cognitively sophisticated therapies. Thus, the overall findings, which
consist of a predominance of CBT interventions , might favor older subjects with the
assumption that they have better developed cognitive skills and derive increased benefits
from the cognitively oriented interventions. With regard to the modest differential effects
based on age in pharmacological studies, these findings might be attributable, in part, to
the predominance of TCA trials and the empirical data that indicate younger children may
not respond favorably to TCAs since their noradrenergic systems are not fully developed
until late adolescence and early adulthood (Murrin et al., 1985).

Psychosocial interventions for depression were somewhat more efficacious when
the average percentage of female subjects was 60% or greater. These findings are
consistent with the data from other reviews that lend support to the trend of differential
efficacy in favor of female subjects (Casey & Berman, 1985; Weisz, Weiss, et al., 1995).
However, these findings were far from compelling and more information is needed to
better understand the relationship between sex and the treatment of early-onset
depression , especially given the epidemiological data, which indicate that the female-tomale ratios for depressive illness begin to approximate the base rates for adult depressive
disorders (i.e., approximately 2:1) during middle to late adolescence. A possible
explanation for the differential outcomes in favor of female subjects might be related to
societal expectations regarding gender-appropriate behavior. That is, given the fact that
females are, in general, socialized and expected to be more emotionally expressive than
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their male counterparts, most forms of psychotherapy in Western culture are congruent
with these socialization forces in that they promote and reinforce increased levels
emotional expression. As such, female subjects potentially have an advantage over the
male subjects because many of our therapeutic regimens are consistent with what they
have been socialized to do from a very early age.

Referral Source
The data on the interaction between referral source and treatment outcome
revealed some interesting trends. In controlled studies, 18 of the 21 (86%) interventions
included nonreferred subjects and yielded an ES of 0.79. Because this ES estimate
encompassed the vast majority of controlled treatments , it closely approximates the
overall ES for controlled studies (0.74). Although three of the controlled studies included
referred subjects and produced a smaller ES (0.44), this finding was not robust and
included two outlier ES estimates near zero. Similarly, the majority of pre-/
posttreatments (80%) included clinically referred subjects and produced a mean effect
size of 1.20, which is commensurate with the overall ES for within-group designs (1.14).
Further, although the mean effect size for nonreferred subjects was somewhat smaller
than the mean effect size for referred subjects, the finding was based on only three studies
so it must considered tentative . In light of these data, it appears that psychosocial
interventions led to substantial reductions in depressive sequelae regardless of whether
the sample was clinically referred or not. In sum, these findings suggest that analog
studies can be used to provide useful data in the treatment of clinically depressed youth.
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Treatment Setting
The school(!!= 15) was the modal setting (75%) for controlled psychosocial
treatments and yielded an average ES (0.75), which was equivalent with the overall effect
size for between-group designs (0.74). Similarly, the vast majority of pre-/posttreatments
took place in outpatient clinics(!!= 12; 80%) and produced a mean effect soze (1.22) that
was roughly commensurate with the overall pre-/post-effect size (1.14). Although there
were only two inpatient psychosocial treatments , they were substantially less effective
(0.29) than interventions conducted in schools or outpatient clinics. A similar pattern of
differential efficacy was apparent in the pharmacological trials as well. Medication trials
conducted in inpatient settings(!!= 6) were essentially ineffective (effect size= -0.06)
when compared to outpatient pharmacotherapy (!! = 8; effect size= 0.26).
Overall , when the treatment setting and the referral source are taken into account,
controlled psychosocial interventions involved mostly nonreferred subjects in school
settings and produced moderately large treatment effects, whereas pre-/posttreatments
included a predominance of clinically referred youngsters in outpatient settings and also
led to substantial reductions in depressive sequelae. Further , it appears that inpatient
treatments for depression are substantially less effective than interventions conducted in
other settings , regardless of whether they are psychosocial or pharmacological in nature .
This finding might be associated with the notion that inpatient subjects are not only
clinically referred, but perhaps more seriously depressed than their peers who are
receiving treatment in schools or outpatient clinics (Wiesz, Donenberg, et al., 1995). In
addition , subjects from inpatient settings often present with a broader range of risk factors
than outpatient groups (e.g., multiple diagnoses , legal and family problems). Thus,
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treatments focused on a specific problem (i.e., depression) may not be adequate for
children who present with more complicated sequelae.

Type of Treatment
Cognitive-behavioral therapy (CBT) was, by far, the most common type of
psychosocial treatment for depressed youth regardless of experimental design or format
(individual, group, family) . Of the 36 treatments reviewed, 17 (47%) were based on
cognitive-behavioral principles and 11 (31%) were cognitive-behavioral group
interventions. Despite the fact that the CBT group was the modal controlled treatment, it
was not the most effective despite a moderately large and robust effect size of 0.69.
Lewinsohn et al. (1990) combined CBT group with family therapy which produced a
mean effect size of 1.45. In addition, two group relaxation regimens (Kahn et al., 1990;
Reynolds & Coats, 1986) were found to be efficacious in reducing depressive symptoms
in children when compared to no-treatment control group subjects (effect size= 1.43).
Other controlled interventions that yielded equivalent or more substantial effect sizes than
CBT group included social skills group therapy (n = 1; effect size= 0.73) and behavioral
problem-solving (n = 1; effect size= 0.68). Thus, although CBT interventions are
frequently implemented and widely regarded as significantly superior to other
interventions (e.g., Jayson, Wood, Kroll, Fraser, & Harrington, 1998), this assertion
might be an overstatement and it is not necessarily supported by the existing empirical
data. At the same time, there were a limited number of non-CBT studies, so the stability
of these findings remains in question.
In terms of the 15 treatments examined in pre-/poststudies, although CBT
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interventions were common(!!= 4; 27%), there was balance and diversity among the
remaining treatments including three social skills groups (20%), three nondirective
individual interventions (20%), interpersonal therapy (n = 1; 7%), individual relaxation
(n = 1; 7%), structured behavior family therapy (n = 1; 7%), and role play therapy (D = 1;

7%). Similar to the findings from controlled treatments, CBT interventions, while
efficacious, were not vastly superior to a number of other types of psychosocial
interventions. Indeed , interpersonal therapy, structured behavioral family therapy , and
nondirective interventions all produced large and roughly commensurate treatment
effects.
Another noteworthy finding regarding treatment type and effect size was the
apparent detrimental impact of attention-placebo conditions. Two studies (Butler et al.,
1980; Liddle & Spence, 1990) included attention-placebo groups that produced a
detrimental effect (-0.83) when compared to no-treatment controls. This was a curious
finding given the intended purpose of an attention-placebo condition, which purportedly
controls for improvement related to variables such as equal time and attention . However,
in the case of these two attention-placebo conditions, simply measuring levels of
depression (i.e., no-treatment controls) was more efficacious than providing a sample of
children with nonspecific time and attention .
In regards to the efficacy of particular types of medications used in the
pharmacological trials, amitriptyline (Elavil) produced the highest ES (0.40; n = 3),
followed by desipramine (Norpramin; 0.39; n = 2) and fluoxetine (Prozac; 0.30; n = 2).
The least effective medications were imipramine (Tofranil; 0.02; n = 4) and nortriptyline
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(Pamelor; -0.15; n = 2). As mentioned previously, the predominant type of medication
used in child pharmacological trials was TCAs, which have not been shown to be
effective in younger groups. On the other hand, the most recent and large controlled
medication trial (Emslie et al., 1997) utilized an SSRI (i.e., Prozac) that proved to be
substantially superior to pill placebo in ameliorating early-onset depression (Mean effect
size= 0.59). As such, this relatively efficacious finding is concealed by the overall effect
size for pharmacological studies.
In sum, the interaction between treatment type and ES reveals some important
findings. For instance, it appears that although CBT produces large and robust treatment
effects, other interventions lead to equally substantial improvements in depression . This
is not necessarily an endorsement of the dodo verdict in terms of early-onset depression
treatment outcomes, but the data do not support the assertion that one type of treatment,
namely cognitive-behavioral therapy, is significantly superior to other types of
interventions. In regards to pharmacological medications, Elavil, Norpramin, and Prozac
appear to be moderately superior to placebo in treating child and adolescent depression
and there is developing evidence that SSRis might be the medication of choice in future
clinical trials.
Further, given the evidence that SSRis are potentially less dangerous and produce
fewer side effects than TCAs, these data provide some compelling and encouraging
reasons to substantially increase our empirical understanding of the efficacy of such
medications for the treatment of depressed youth.
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Other Treatment Variables
The data regarding the interaction of frequency (i.e. , number of sessions) and
treatment outcome for depressed youth revealed some interesting trends. For example,
as mentioned above, the length of the pharmacological trials and the TCA studies in
particular was perhaps too brief (i.e., 4-8 weeks) to detect treatment effects , given that it
often takes up to a month to evidence benefits.

In addition, there was a modest negative

relationship between the length of therapy (i.e., number of weeks) and the mean effect
size (r = -0.40 ; .Q = .07). That is, as the number of treatment weeks increased, the average
effect size decreased. As such, these data might indicate that the treatment effects level
off or diminish over time, but these findings should be interpreted with caution given the
fact that they were not statistically significant nor practically compelling. Further, this is
an important empirical question given the evidence from the adult literature , which
indicates that most of the benefits of psychotherapy are obtained during the first 8-10
sessions . However, this does not necessarily imply that important gains are not made
after the first 10 sessions. Indeed , in a number of health-related treatments (e.g. ,
chemotherapy for cancer) , the patient gets substantially worse before getting better. Thus,
for individuals who suffer from some forms of depression , it is possible that the course of
the disease worsens before improving, and discontinuing treatment prematurely based on
inadequate data would be a disservice to clients. In sum, more information is needed to
better understand the relationship between these variables and treatment efficacy for child
and adolescent depression, especially given the current economic climate in which brief,
empirically supported treatments are the battle cry of many, if not all, insurance
companies and managed-care organizations.
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Assessment Measures
As described previously, measuring treatment efficacy depends exclusively on
assessment technology. While there were a number of studies that employed multiple
depression measures to determine outcome (e.g., Brent et al., 1997; Emslie et al., 1997;
Kahn et al., 1990), there was a general overreliance on self-report measures across
psychosocial and pharmacological studies. Thus, given the evidence that depression, as
measured by self-report devices, attenuates over time and repeated administrations, it is
likely that some of the improvement depression treatment studies was attributable to
extraneous variables such as the mere passage of time and regression towards the mean
(Hsu, 1995). These data highlight the importance of no-treatment control groups and a
broad array of assessment devices in clinical trials.
In addition, every intervention study involves demand characteristics. For
example, when children present for treatment, they are aware that others expect them to
improve and might therefore self-report fewer symptoms in an effort to confirm that
expectation (Orne, 1969; Rosenthal, 1995). It is plausible that older relative to younger
participants and female compared to male respondents are more sensitive to the demand
characteristics of the treatment and testing situations. Thus, the larger effect size
estimates for older subjects and female majority samples may reflect expectancy effects
rather than genuine effects of treatment.
Furthermore, practical comparisons of two different measures within the same
study indicated that some instruments revealed moderately divergent effect sizes. For
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instance , the effect size difference between two self-report measures of depression in one
study (Kahn et al., 1990) was substantial (0.65). In other examples, there were discrepant
findings within the same study depending on the source of the outcome data. Using the
percent improved data, the ES in the study by Geller et al. (1990) was -0.61 as compared
to the SMDES on the CDRS (0.49). Moreover, in the study by Geller et al. (1992), the
effect size based on the percent improved was 0.46 as compared to a less impressive effect
size on the CDRS of 0.12. Thus, these data illustrate rather clearly that it can be
dangerous to make firm decisions about treatment efficacy given the limitations of
assessment procedures. On the other hand, effect size estimates based on two different
measures were remarkably convergent in another study (e.g., 0.04 difference between BDI
and RADS ; Reynolds & Coats, 1986). Overall, it appears that the best way to prevent a
great deal of measurement error in child depression outcome studies is to administer a
broad array of devices that purport to measure depression and related constructs.

Therapist Variables
Professional therapists consistently produced a higher mean effect size in treating
depressed youth than either graduate trainees or paraprofessional therapists , regardless of
the experimental design. Graduate trainees, in turn, were more effective than their
paraprofessional counterparts who produced the smallest effect sizes overall. These data
are congruent with the findings from large meta-analytic reviews which indicate that
professional therapists are more effective than their less trained counterparts (Stein &
Lambert, 1995; Weisz et al., 1987).

116

Similar to the data regarding referral source and treatment setting, the majority of
controlled treatments (with nonreferred subjects in schools) were most often led by
graduate trainees. In contrast, pre-/posttreatments (with referred subjects in outpatient
clinics) were led predominantly by professional therapists. Nonetheless, these findings
lend support to the idea that increased levels of training and experience in psychotherapy
lead to enhanced treatment outcomes, much to the delight of graduate training directors
everywhere.

Severity of Illness and Comorbidity
Overall, it appears that psychosocial interventions for depressed youth were
effective regardless of whether the children were treated based on depressive
symptomatology or a diagnosis of major depressive disorder and/or dysthyrnia. In
contrast, the mean effect sizes of prevention studies were substantially lower across
controlled and pre-/posttreatment designs . This finding was expected, based on the
intuitive assumption that the children in at-risk studies were less depressed that the
subjects in symptom- or diagnosis-based trials . Further, in prevention studies, the failure
to detect elevated levels of depression is not only expected , but it is an artifact of
measurement limitations (i.e., floor effect, limited sensitivity to low levels of depression) .
The lack of treatment effect in prevention studies does not diminish their importance .
Indeed , it is difficult to assess when something did not happen! At the same time , it
illustrates the need to follow at-risk samples longitudinally in comparison to no-treatment
controls .
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Unfortunately, as mentioned previously, the data regarding comorbidity were
limited. This was especially disappointing given the evidence that comorbid conditions
involving depression lead to poorer outcomes, prolonged morbidity, and increased
vulnerability to future bouts of depression (e.g., Kovacs , 1998; Newman et al., 1996).
However, there was one provocative finding regarding the interaction of comorbidity and
depression treatment outcome. In a pharmacological trial in which the efficacy of
imipramine was examined, Hughes, Preskom, Wrona, et al. (1990) reported that patients
with major depressive disorder and comorbid anxiety disorders responded much better to
the medication (mean effect size= 1.02) than those with major depressive disorder and
comorbid conduct disorder and/or oppositional defiant disorder (mean effect size=
-0.88. Thus, while there appeared to be null main effects, the data clearly revealed
evidence of differential efficacy when comorbid diagnoses were taken into account.
Further research is needed to better understand the relationship between comorbid
diagnoses and the treatment of child and adolescent depression.

Quality of Study
There is a moderately strong and statistically significant relationship between the
quality of study and the mean effect sizes for early-onset depression outcome studies. This
finding was contrary to the hypothesis proposed by Wilson and Rachman (1983), wherein
it was suggested that methodologically weaker studies might skew the results from metaanalytic reviews in the direction of an overestimation of treatment effects. However, the
data from the present study were congruent with the findings reported by Weiss and Wiesz
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Weiss and Wiesz (1990) whereby increased levels of methodological rigor were
associated with higher mean effect size estimates . Further, Weiss and Wiesz suggested
that experimental factors accounted for almost as much variance as the more substantive
elements such as treatment type and age. Therefore, these data provide compelling
evidence that methodological factors should be carefully considered during the
development and implementation of experimental treatments for child and adolescent
depression . At the same time, it appears less likely that studies with more limited
controls will dangerously skew the findings.

Summary and Clinical Implications

The overall findings of this meta-analysis indicate that several different
psycho social interventions for early-onset depression produce moderate to large treatment
gains that are clinicall y meaningful for many afflicted youth . Further , it appears that
psychosocial treatments are, in general , superior to pharmacological regimens in treating
depressed children and adolescents. However , there is also recent evidence that SSRls
such as fluoxetine are efficacious, and they will likely play an increased role in the
management of affective illness in youngsters .
In terms of the clinical implications of these findings , it appears that two related
but unique bodies of literature within the domain of child depression treatment studies
have developed. On the one hand, there are a number of controlled studies with
nonreferred children suffering from depressive symptoms who derive substantial benefit
from school-based interventions led mostly by graduate students . On the other hand,
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there are a large number of pre-/poststudies with referred children suffering from
depressive diagnoses who benefit greatly from outpatient treatments led predominantly by
professional therapists. Taken together, the implications are promising and likely
generalizable to everyday clinical practice since the findings are not simply based on
analogue samples or mildly depressed youngsters. Further, it appears that clinicians can
select from and even combine various treatment technologies that produce roughly
commensurate effects in ameliorating depressive sequelae in their clients. Finally, given
the data regarding the relative superiority of psychosocial interventions over medication
for depressed youth, clinicians should consider psychosocial treatments to be first-line
interventions until there are more definitive answers regarding the efficacy and safety of
pharmacotherapy for child and adolescent depression. This may contradict the oft-held
assumption that medication is the treatment of choice when compared to psychosocial
alternatives to treating psychopathological disorders. However, based on the findings
from this review, this assumption should be challenged and the present data should be
integrated into clinical practice, regardless of whether one is a pediatrician, psychologist,
psychopharmacologist, or psychiatrist. Furthermore, while it is true that recent results
from pharmacological trials have showed increased efficacy (e.g., Emslie et al., 1997),
one should remain mindful of the fact that psychosocial interventions produce moderate
to large treatment effects without the possibility of noxious side effects or an adverse
impact on child development.
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Limitations and Future Research

Perhaps the most compelling limitation of the present investigation is the fact that
the vast majority of the 37 psychosocial and pharmacological studies (29; 78%) were
published after 1990. Thus, this is a relatively new and quickly expanding body of
literature. As such, it was a challenge to keep up with all of the new developments
regarding the treatment of early-onset depression and it is likely that some important
findings were not included in the present analysis (i.e., file drawer problem, unpublished
manuscripts, etc.). Another limitation is based on the calculation of ES for
pharmacological trials. As mentioned previously, the pharmacological findings represent
a synthesis of potentially flawed data wherein effect sizes were calculated based on a
transformation of divergent dichotomous variables (i.e., improvement in the active and
placebo conditions).
Given the overall findings and these limitations, there are several important
recommendations regarding future empirical efforts to investigate the efficacy of
treatments for early-onset depression . First, future researchers should explicitly report
findings based on age, sex, and comorbid conditions , in light of the limited interactional
data that could be obtained regarding these important variables. Second, more consistent
improvement criteria should be developed for pharmacological trials to facilitate more
useful comparisons across studies. Third, researchers should attend closely to
methodological variables when developing future outcome trials given the positive
correlation between experimental rigor and effect size. Finally, similar to adult studies,
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large controlled clinical trials examining the efficacy of psychosocial and
pharmacological interventions for child and adolescent depression should be developed
and implemented to provide additional insights into this vital health-care issue.
In terms of how these findings might inform policy, a few recommendations are
offered. First, given the evidence that child and adolescent depression is prevalent and
leads to a number of negative outcomes, diligent efforts are needed to fund and develop
effective treatments for these disabling conditions.

Second, more information regarding

the prevention, identification, and treatment of early-onset depression should be
disseminated to a broad range of health-care providers (e.g., pediatricians), child service
professionals (e.g., day-care providers), and child-focused settings (e.g., schools).
Finally, the treatment of early-onset depression should be considered a vital health-care
issue worthy of considerable time and expense in hopes of easing the suffering of a
substantial number of young people.
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APPENDIX

APPENDIX
Coding Form

Column(s)

ES!

ES2

ES3

ES4

ES5

ES6

Variable

1,2

Study ID #

3,4

ES #

5,6

Year of Publication

7-10

Mean age at beginning

11-13

% female

14- 16

Total n Experim ental

17-19

Total n Control

20

Referral: I= clinical
2=nonclinical

21

Setting: I =school ; 2=outpt ;
3=inpt

22

Therapist: 1=paraprofes sional ;
2=graduate ; 3=professional

23

Design : I =pre/post ;
2=exp (i.e., control group)

24

Com orb id Dx: I =yes; 2=no
Type :

25

Level of intervention :
1=prevention
2=symptomatolog y
3=diagnosis

26 ,27

Total # of sessions

28-30

Total # of weeks

31-33

Total # of hours

34

Type of intervention:
1=ind; 2=group ; 3=famil y
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35,36

Treatment modality :
I =CBT; 2=RP; 3=Relax ; 4=SS;
5=Psyed ; 6=NDST ; 7=IPT; 8=fam ;
9=UC; IO=Con ; J J=plac ;
J2=medication

37

Self-Report Measure :
I =CDI ; 2=BDI; 3=RCDS ;
4=HRSD ; 5=CESD ; 6=RADS ;
7=MFQC ; other (specify)

38

Dx Interview : I =yes ; 2=no
Type :
Other measures : I =yes; 2=no
Type:
SMDES Comparison
write in ...

39-43

SMDES

±._. __

44

Follow-up : I =yes; 2=no

45-47

Length of Follow-up (wks)

48- 52

Follow-up SMDES

53

Quality of Study : Validity :
1=unacceptable
2=poor
3=fair
4=good
5=excellent
Threats to Validity (0-3) :
maturation :
history:
testing :
instrumentation:
regression :
selection bias :
experimental mortality :
O=not a plausible threat
I =minor threat
2=plausible threat
3=by itself could explain findings

Note : Aer Exer=Aerobic Exercise; Alt-Tx=Alternative Treatment; Attn-Plac=Attention-Placebo
Group ; CBT-G=Cognitive-Behavioral Therapy-Group; CBT-I=Cognitive-Behavioral TherapyIndividual; Consult=Consultation; F=Family Therapy ; IPT-I=Interpersonal PsychotherapyIndividual; NFI-I =Non-focused Intervention-Individual ; NST-I=Non-Directive Supportive
Therapy-Individual; P=Parent; PS-G=Problem-Solving Group ; PsyEd-G=Psychoeducational
Group ; Rlx-I=Individual Relaxation Therapy ; Rlx-G=Group Relaxation Therapy; RP-G=RolePlay Group; SS-G=Social Skills Group ; SBFT=Structured Behavior Family Therapy.
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1991 - 1993

Counselor, United Methodist Family Services, Richmond , Virginia.
Provided counseling and supervision to emotionally disturbed , adjudicated ,
and chemically dependent children in a long-term residential
treatment milieu. Led extended hiking , rock climbing , and camping
trips . Facilitated groups and high and low ropes course events.
Hours : 4300 .

1992 - 1993

Chemical Dependency Counselor/Psychiatric Technician, Charter
Westbrook Hospital , Richmond , Virginia.
Facilitated chemical dependency treatment groups on the child and adolescent
acute and long-term inpatient units. Supervised patient s and served
as a member of an interdisciplinary treatment team. Direct Hours :
400 .

1990 - 1991

Senior Counselor, Therapeutic Community , Shalom et Benedictu s,
Stephenson, Virginia.
Provided counseling to chemically dependent , adjudicated , and emotionally
disturbed adolescents . Facilitated therap y groups and treatment team
meetings . Responsible for clinical supervision and staff scheduling.
Assisted the Program Director in the daily management of the
therapeutic milieu . Hours : 3800 .

1989 - 1990

Community Assistance Coordinator, Shalom et Benedictus , Stephenson ,
Virginia .
Provided counseling and consultation to children and their families .
Facilitated support groups in city and county schools such as :
children of divorce , substance abuse aftercare , and social skills .
Hours : 2000.

1989 - 1991

Counseling Consultant, Shenandoah University Counseling Clinic ,
Winchester , Virginia .
Provided individual and group counseling for students . Served as a crisis
interventionist and administered substance abuse assessments. Direct
Hours : 600 .

1986 - 1989

Student Director, Rapline , Wardenburg Student Health Center , University of
Colorado at Boulder.
Served as a crisis interventionist trained to deal with suicide, domestic
violence, rape, depression , and other conditions . Responsibilities
included : recruitment, training, and supervision of phone counselors .
Direct Hours: 400 .
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Clinical (Year-Long) Practica
1997 - 1998

Behavioral Health Unit, Logan Regional Hospital, Logan, Utah.
Conducted psychological evaluations, wrote psychological reports , and cofacilitated group therapy sessions on an inpatient psychiatric unit.
Participated in interdisciplinary treatment team meetings.

1997 (Summer)

Psychology Community Clinic , Department of Psychology , Utah State
University, Logan , Utah .
Provided individual , couples, and family psychotherapy under the supervision
of licensed clinical psychologists. Wrote psychological reports.

1996 - 1997

Utah State University Counseling Center , Logan , Utah.
Provided individual, couples , and group therapy under the supervision of
licensed clinical psychologists . Conducted intake assessments .

1995 - 1996

Ogden City School District, Ogden , Utah.
Conducted comprehensive psychoeducational assessments, conducted
behavioral observations , and facilitated groups for preschoolers with
developmental disabilities and behavioral disorders.

1994 - 1995

Psychology Community Clinic , Department of Psychology , Utah State
University, Logan , Utah.
Provided individual, couples , and family psychotherapy under the supervision
of licensed clinical psychologists . Wrote psychological reports .

Clinical Consultation
1995 - 1998

Psychometrician , for David Stein, PhD , Private Practitioner , Logan , Utah .
Conducted intellectual , memory , and psychological assessments as part of
comprehensive vocational rehabilitation/disability evaluations .
Teaching Experience

1997

Instructor, Psychology 510/610, History and Systems , Utah State
University, Logan, Utah .
Responsibilities included: lecture preparation and delivery , exam construction
and administration, and grading.

1996

Graduate Teaching Assistant, Psychology 631, Intellectual Assessment , Utah
State University , Logan , Utah .
Responsibilities included: grading assessment protocols and reports, and
didactic instruction.

1996

Instructor, Psychology 321 , Abnormal Psychology , Utah State University
Extension, Logan, Utah.
Responsibilities included: lecture preparation and delivery, exam
construction and administration, and grading .

1995 - 1996

Graduate Teaching Assistant, Psychology IO1, General Psychology, Utah
State University .
Responsibilities included: lecture preparation and delivery, supervision of 6
lab instructors, exam construction and administration, tutoring, exam
review sessions, and grading.
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1993 - 1994

Adjunct Training Faculty, Virginia Department of Youth and Family
Services, Richmond , Virginia.
Trained Department personnel on issues such as: chemical dependency, drug
trafficking, milieu treatment for juvenile offenders, adventure-based
treatment, and ropes course facilitation.

1987 - 1988

Drug and Alcohol Peer Educator, Wardenburg Student Health Center ,
University of Colorado at Boulder.
Presented drug and alcohol seminars to University and community groups.

1987 - 1988

Teaching Assistant, General Psychology, University of Colorado at Boulder.
Responsibilities included: lecturing, tutoring , exam review sessions, and
grading.
Research Experience

1997 - present

Child clinical research with Dr. Susan Crowley , Utah State University .
Integrative review of the efficacy of treatments for childhood depression .

1996 - 1997

Child health psychology research with Ors . Kevin Masters and Gretchen
Gimpel , Utah State University. Worked as part of research team examining a
number of variables related to child health psychology such as: asthma ,
exercise, and nutrition.

1996

Child clinical research with Dr. Ken Merrell, Utah State University.
Convergent validity study of several self-report instruments that purport to
measure depression, anxiety , and other internalizing symptoms.

1995 - 1997

Child clinical research with Dr. Ken Merrell , Utah State University . An
investigation of the temporal stability of self-reported internalizing symptoms
in elementary-age children .

1994 - 1997

Child and adolescent substance abuse research with Dr. David Stein, Utah
State University. Three separate studies on : the efficacy ofD.A.R.E. , milieu
treatment for juvenile drug dealers, and the effectiveness of alcoholism
treatments.

1988

Researcher I, Pediatric Psychiatry, National Jewish Center for Immunology
and Respiratory Medicine , Denver , Colorado. Responsibilities included the
collection of data via: pediatric phlebotomy , viral cultures, videotaped
observation, and interviews .

1987 - 1988

Research Assistant, Memory Assessment Clinics (UC-B), Advanced
Psychometrics Corporation , Rockville , Maryland. Administered assessment
instruments including computer-based memory tests and selected W AIS-R
subtests.

1987

Research Assistant, Raimy Clinic, Clinical Psychology Department,
University of Colorado at Boulder. Conducted literature reviews, entered
data , and helped to develop clinical research instruments for PhD students .

1986

Research Assistant, Institute for Behavioral Genetics, Boulder, Colorado .
Served as a member of a research team examining the environmental and
genetic influences on varied behaviors. Responsible for data collection and
data entry.
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Publications
Michael, K.D., & Merrell, K.W. (1998). The reliability of children's self-reported internalizing
symptoms over brief- to medium-length time intervals. Journal of the American Academy of
Child and Adolescent Psychiatry R 194-201.
Merrell, K.W., Anderson, K.E., & Michael, K.D. (1997). Convergent validity of the
Internalizing Symptoms Scale for Children with three self-report measures of internalizing
problems. Journal of Psychoeducational Assessment, 15, 56-66 .
Michael, K. (1996). The importance of integrating research & clinical practice. Counselor, 9(10),
11-12.
Stein, D., & Michael, K. ( 1995). Outcome research and clinical practice: Critical skills for
counselors. Counselor, 7(8), 8-13 .
Michael, K., & Bailey, K. (1995) . Treatment versus security in correctional settings: A useful
distinction or a harmful dichotomy? Counselor, 3(4 ), 19-20.
Michael, K. ( 1995, April). 16 ways to make your child smile. CFP news: A quarterly update on
the Community-Family Partnership Project, Vol. 7, #1, p. 5.
Michael , K., & Wall , C. (1994). Treating juvenile drug dealers. Counselor, 5(6), 26-29.
Michael, K. ( 1987). The Justice Department's drug-free workplace program. United States
Department of Justice, Washington, DC.

Editorial Experience

Guest Editor, Special Issue on Substance Abuse Research, Counsel.or, September/October,

1996.

Presentations
Michael, K. D., & Crowley, S. L. (1998, August). The efficacy of psychological treatments for
childhood depression: A meta-analytic review. Paper presented at the Annual Convention
of the American Psychological Association, San Francisco, CA.
Michael, K. D., & Crowley, S. L. (1998, April) . Childhood depression treatment efficacy : Impact
of demographic and method variables . Paper presented at the Annual Convention of the
Western Psychological Association , Albuquerque, NM.
Michael, K. ( 1997, September). Innovations in assessing internalizing symptoms in children:
The Internalizing Symptoms Scale for Children . Paper presented as part of a symposium on
child assessment at the seventh annual Virginia Beach Conference on Children and
Adolescents with Emotional and Behavioral Disorders, Virginia Beach, VA.
Michael, K., Stein, D., & Hawkins, N. ( 1997, October). The effectiveness of alcoholism
treatments. Paper presented at the 19th annual Utah Conference on Substance Abuse,
Ogden, UT.
Gimpel, G., Masters, K., Rollins, L., Michael, K., & Schultz, L. (1997, November). Knowledge
and beliefs regarding exercise among junior high students. Paper presented at the 31st
annual Convention of the Association for Advancement of Behavior Therapy, Miami
Beach, FL.
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Michael, K., & Merrell , K. (I 997, April). An investigation of the temporal stability of selfreported internalizing symptoms in elementary-age children . Paper presented at the
Convention of the National Association of School Psychologists, Anaheim, CA.
Stein, D., & Michael, K. ( 1996, October). The efficacy of D.A.R.E. Paper presented at the 18th
annual Utah Conference on Substance Abuse, Park City, UT.
Michael, K., & Stein, D. (1995, October). Milieu treatment for adolescent drug dealers. Paper
presented at the 17th annual Utah Conference on Substance Abuse, Park City, UT.
Michael, K. (1995, February). Substance abuse identification and intervention strategies for
family support professionals: A two-day inservice . Community-Family Partnership Project,
Center for Persons with Disabilities, Utah State University, Logan, UT.
Michael, K., & Derr, D. ( 1994, August) . Experiential education: Ropes course and rock climbing
facilitator training. Technical Training, Virginia Department of Youth and Family
Services , Beaumont, VA.
Michael, K., & Hales, L. (1994 , July/ August). The 12-core functions of substance abuse
counselors. Academy for Staff Development, Virginia Department of Corrections , Crozier ,
VA.
Michael, K. (1993 , December) . Youth empowerment: Therapeutic communities for juvenile sex
offenders. Program Training, Virginia Department of Youth and Family Services,
Richmond, VA.
Michael, K., & Hawkins , M. (I 992, October). Treating alcohol and other drug problems in a
group process milieu. Paper presented at the 18th annual conference of the National
Association of Peer Group Agencies , Richmond , VA .
Michael , K. ( 1990, February). The relationship between substance abuse and crime. Paper
presented at the National Organization for Victim Assistance, Washington, DC .
Michael, K. ( 1988, April). Psychosexual development and homosexuality. Thesis presented at
the Rocky Mountain Psychological Association Convention , Snowbird , UT.
Michael, K. (1986-89). Crisis intervention and paraprofessional counseling. Crisis Counselor
Training , Rapline Crisis Intervention Services , Boulder , CO.

Other Experience
1987

Management Assistant, to the Assistant Attorney General for Personnel and
Administration, United States Department of Justice, Washington, DC. Reviewed
and edited the Department's manual on employee urinanalysis procedures .
Professional Licensure and Certifications

C.S.P., Certified School Psychologist, Utah State Office of Education, Salt Lake City, Utah.
L.S .A.C ., Licensed Substance Abuse Counselor (1997 - present), Utah Division of
Occupational and Professional Licensing.
C.A.C., Certified Addictions Counselor (1989 - present), Utah Association of Alcoholism and
Drug Abuse Counselors; (formerly) Substance Abuse Certification Alliance of Virginia.
C.C.S., Certified Clinical Supervisor (1993 - present), Utah Association of Alcoholism and Drug
Abuse Counselors; (formerly) SACAVA.
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C.S.A .C.,Certijied Substance Abuse Counselor (1994 - present), Board of Professional
Counselors and Marriage and Family Therapists , Virginia Department of Health
Professions.
Selected Conferences and Workshops Attended
An Afternoon with a Master, Irvin Yalom , MD , University Counseling Center , Utah State
University, April, 1998.
Anxiety Disorders in Youth: Interventions for Children and Families , Thomas Ollendick , PhD,
Seventh Annual Virginia Beach Conference Workshop , September, 1997.
Raising Children in a Socially Toxic Environment , James Garbarino , PhD, Utah State University ,
January, 1997.
Insid e the Criminal Mind, Stanton Samenow, PhD, Benchmark Health Systems, Salt Lake City,
Utah , May , 1996.
Exploring the Power of Group, Robert Weber , PhD, University Counseling Center, Utah State
University , April , 1996.
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